<div class="prescribing-wrapper">
    <div class="prescribing-info-box">

<!-- coppying from desktop --> 
<svg id="desktop" xmlns="http://www.w3.org/2000/svg" width="auto" height="7836" viewBox="0 0 auto 7836">
    <g id="desktop" transform="translate(0.75)">
        <g id="Group_21" data-name="Group 21" transform="translate(-335.75 -102)">
            <text id="These_highlights_do_not_include_all_the_information_needed_to_use_AKLIEF_Cream_safely_and_effectively._See_full_prescribing_information_for_AKLIEF_Cream._AKLIEF_trifarotene_cream_for_topical_use_Initial_U.S._Approval:_2019_-_-_INDICATIONS_AND" data-name="These highlights do not include all the information needed to use AKLIEF® Cream safely and effectively. See full prescribing information for AKLIEF Cream.AKLIEF (trifarotene) cream, for topical useInitial U.S. Approval: 2019————-————-——INDICATIONS AND" transform="translate(336 134)" font-size="16" class="sofiapro-bold" font-weight="700">
                <tspan x="0" y="16">These highlights do not include all the information needed to use </tspan>
                <tspan x="0" y="35">AKLIEF</tspan>
                <tspan y="35" font-size="9.333" baseline-shift="5.33279994943018">®</tspan>
                <tspan y="35" xml:space="preserve"> Cream safely and effectively. See full prescribing </tspan>
                <tspan x="0" y="54">information for AKLIEF Cream.</tspan>
                <tspan x="0" y="73">AKLIEF (trifarotene) cream, for topical use</tspan>
                <tspan x="0" y="92">Initial U.S. Approval: 2019</tspan>
                <tspan x="0" y="111"></tspan>
                <tspan x="0" y="130">————-————-——INDICATIONS AND USAGE——————————-</tspan>
                <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                    <tspan x="0" y="149">AKLIEF Cream is a retinoid indicated for the topical treatment of </tspan>
                    <tspan x="0" y="168">acne vulgaris in patients 9 years of age and older. (1)</tspan>
                </tspan>
                <tspan x="0" y="187"></tspan>
                <tspan x="0" y="206">—————-————DOSAGE AND ADMINISTRATION—————————</tspan>
                <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                    <tspan x="0" y="225" xml:space="preserve">•   For topical use only. Not for oral, ophthalmic or intravaginal </tspan>
                    <tspan x="0" y="244" xml:space="preserve">     use.</tspan>
                    <tspan x="0" y="263" xml:space="preserve">•   Apply a thin layer of AKLIEF Cream to the affected areas of the        </tspan>
                    <tspan x="0" y="282" xml:space="preserve">     face and/or trunk once a day, in the evening, on clean and dry </tspan>
                    <tspan x="0" y="301" xml:space="preserve">     skin. Avoid contact with the eyes, lips, paranasal creases, and </tspan>
                    <tspan x="0" y="320" xml:space="preserve">     mucous membranes. (2)</tspan>
                </tspan>
                <tspan x="0" y="339"></tspan>
                <tspan x="0" y="358">—————————DOSAGE FORMS AND STRENGTHS———————-—</tspan>
                <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                    <tspan x="0" y="377">Cream: 0.005% trifarotene. (3)</tspan>
                </tspan>
                <tspan x="0" y="396"></tspan>
                <tspan x="0" y="415">————————————CONTRAINDICATIONS————————————</tspan>
                <tspan font-family="SofiaProCondensed-Regular, Sofia Pro Condensed" font-weight="400">
                    <tspan x="0" y="434">None (4)</tspan>
                </tspan>
            </text>
            <text id="HIGHLIGHTS_OF_PRESCRIBING_INFORMATION" data-name="HIGHLIGHTS OF PRESCRIBING INFORMATION" transform="translate(336 102)" font-size="16" class="sofiapro-bold" font-weight="700">
                <tspan x="61.648" y="16">HIGHLIGHTS OF PRESCRIBING INFORMATION</tspan>
            </text>
            <text id="_-_WARNINGS_AND_PRECAUTIONS_-" data-name="——-———————WARNINGS AND PRECAUTIONS—————————-" transform="translate(850 102)" font-size="16" class="sofiapro-bold" font-weight="700">
                <tspan x="1.552" y="16">——-———————WARNINGS AND PRECAUTIONS—————————-</tspan>
            </text>
            <text id="_Skin_irritation:_Erythema_scaling_dryness_and_stinging_burning_may_be_experienced_with_use_of_AKLIEF_Cream._Use_a_moisturizer_from_the_initiation_of_treatment_and_if_appropriate_reduce_the_frequency_of_application_of_AKLIEF_Crea" data-name="•   Skin irritation: Erythema, scaling, dryness, and stinging/burning may be experienced with use of AKLIEF Cream. Use a moisturizer from the initiation of treatment, and, if appropriate, reduce the frequency of application of AKLIEF Crea" transform="translate(850 134)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="16" xml:space="preserve">•   Skin irritation: Erythema, scaling, dryness, and stinging/burning </tspan>
                <tspan x="0" y="35" xml:space="preserve">     may be experienced with use of AKLIEF Cream. Use a moisturizer </tspan>
                <tspan x="0" y="54" xml:space="preserve">     from the initiation of treatment, and, if appropriate, reduce the </tspan>
                <tspan x="0" y="73" xml:space="preserve">     frequency of application of AKLIEF Cream, suspend or </tspan>
                <tspan x="0" y="92" xml:space="preserve">     discontinue use. (5.1)</tspan>
                <tspan x="0" y="111" xml:space="preserve">•   Ultraviolet Light and Environmental Exposure: Minimize exposure </tspan>
                <tspan x="0" y="130" xml:space="preserve">     to sunlight and sunlamps. Use sunscreen and protective clothing </tspan>
                <tspan x="0" y="149" xml:space="preserve">     over treated areas when exposure cannot be avoided. (5.2)</tspan>
                <tspan class="sofiapro-bold" font-weight="700">
                    <tspan x="0" y="168"></tspan>
                    <tspan x="0" y="187">—————-——————ADVERSE REACTIONS————————————</tspan>
                </tspan>
                <tspan x="0" y="206">Most common adverse reactions (incidence ≥ 1%) in patients treated </tspan>
                <tspan x="0" y="225">with AKLIEF Cream were application site irritation, application site </tspan>
                <tspan x="0" y="244">pruritus, and sunburn (6).</tspan>
                <tspan class="sofiapro-bold" font-weight="700">
                <tspan x="0" y="263">To report SUSPECTED ADVERSE REACTIONS, contact </tspan>
                <tspan x="0" y="282">Galderma Laboratories, L.P. at 1-866-735-4137 or </tspan>
                <tspan x="0" y="301">FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</tspan>
                <tspan x="0" y="320">See 17 for PATIENT COUNSELING INFORMATION </tspan>
                <tspan x="0" y="339" xml:space="preserve">and FDA-approved patient labeling.                       Revised: 10/2019</tspan>
                <tspan x="0" y="358"></tspan>
            </tspan>
        </text>
        <text id="_1_INDICATIONS_AND_USAGE_2_DOSAGE_AND_ADMINISTRATION_3_DOSAGE_FORMS_AND_STRENGTHS_4_CONTRAINDICATIONS_5_WARNINGS_AND_PRECAUTIONS_5.1_Skin_Irritation_5.2_Ultraviolet_Light_and_Environmental_Exposure_6_ADVERSE_REACTIONS_6.1_Clinical_Trials_Experie" data-name="1 INDICATIONS AND USAGE2 DOSAGE AND ADMINISTRATION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Skin Irritation 5.2 Ultraviolet Light and Environmental Exposure 6 ADVERSE REACTIONS 6.1 Clinical Trials Experie" transform="translate(336 653)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="0" y="16">1 INDICATIONS AND USAGE</tspan>
            <tspan x="0" y="35">2 DOSAGE AND ADMINISTRATION</tspan>
            <tspan x="0" y="54">3 DOSAGE FORMS AND STRENGTHS</tspan>
            <tspan x="0" y="73">4 CONTRAINDICATIONS</tspan>
            <tspan x="0" y="92">5 WARNINGS AND PRECAUTIONS</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="111" xml:space="preserve">    5.1 Skin Irritation</tspan>
                <tspan x="0" y="130" xml:space="preserve">    5.2 Ultraviolet Light and Environmental Exposure</tspan>
            </tspan>
            <tspan x="0" y="149">6 ADVERSE REACTIONS</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="168" xml:space="preserve">    6.1 Clinical Trials Experience</tspan>
            </tspan>
            <tspan x="0" y="187">7 DRUG INTERACTIONS</tspan>
            <tspan x="0" y="206">8 USE IN SPECIFIC POPULATIONS</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="225" xml:space="preserve">    8.1 Pregnancy</tspan>
                <tspan x="0" y="244" xml:space="preserve">    8.2 Lactation</tspan>
                <tspan x="0" y="263" xml:space="preserve">    8.4 Pediatric Use</tspan>
                <tspan x="0" y="282" xml:space="preserve">    8.5 Geriatric Use</tspan>
            </tspan>
        </text>
        <text id="_11_DESCRIPTION_12_CLINICAL_PHARMACOLOGY_12.1_Mechanism_of_Action_12.2_Pharmacodynamics_12.3_Pharmacokinetics_13_NONCLINICAL_TOXICOLOGY_13.1_Carcinogenesis_Mutagenesis_Impairment_of_Fertility_14_CLINICAL_STUDIES_16_HOW_SUPPLIED_STORAGE_AND" data-name="11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND" transform="translate(850 653)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="0" y="16">11 DESCRIPTION</tspan>
            <tspan x="0" y="35">12 CLINICAL PHARMACOLOGY</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="54" xml:space="preserve">    12.1 Mechanism of Action</tspan>
                <tspan x="0" y="73" xml:space="preserve">    12.2 Pharmacodynamics</tspan>
                <tspan x="0" y="92" xml:space="preserve">    12.3 Pharmacokinetics</tspan>
            </tspan>
            <tspan x="0" y="111">13 NONCLINICAL TOXICOLOGY</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="130" xml:space="preserve">    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</tspan>
            </tspan>
            <tspan x="0" y="149">14 CLINICAL STUDIES</tspan>
            <tspan x="0" y="168">16 HOW SUPPLIED/STORAGE AND HANDLING</tspan>
            <tspan x="0" y="187">17 PATIENT COUNSELING INFORMATION</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="206">*Sections or subsections omitted from the</tspan>
                <tspan x="0" y="225">full prescribing information are not listed.</tspan>
            </tspan>
        </text>
        <text id="_1_INDICATIONS_AND_USAGE_AKLIEF_Cream_is_a_retinoid_indicated_for_the_topical_treatment_of_acne_vulgaris_in_patients_9_years_of_age_and_older._2_DOSAGE_AND_ADMINISTRATION_Apply_a_thin_layer_of_AKLIEF_Cream_to_the_affected_areas_once_daily_in_" data-name="1   INDICATIONS AND USAGE AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. 2   DOSAGE AND ADMINISTRATION Apply a thin layer of AKLIEF Cream to the affected areas once daily, in " transform="translate(336 1006)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="0" y="16" xml:space="preserve">1   INDICATIONS AND USAGE</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="35" xml:space="preserve">     AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.</tspan>
            </tspan>
            <tspan x="0" y="54" xml:space="preserve">2   DOSAGE AND ADMINISTRATION</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="73" xml:space="preserve">     Apply a thin layer of AKLIEF Cream to the affected areas once daily, in the evening, on clean and dry skin.</tspan>
                <tspan x="0" y="92" xml:space="preserve">     •   One pump actuation should be enough to cover the face (i.e., forehead, cheeks, nose, and chin).</tspan>
                <tspan x="0" y="111" xml:space="preserve">     •   Two actuations of the pump should be enough to cover the upper trunk (i.e., reachable upper back, shoulders and chest). One </tspan>
                <tspan x="0" y="130" xml:space="preserve">          additional pump actuation may be used for middle and lower back if acne is present.</tspan>
                <tspan x="0" y="149">The use of a moisturizer is recommended as frequently as needed from the initiation of treatment.</tspan>
                <tspan x="0" y="168">Avoid contact with the eyes, lips, paranasal creases, mucous membranes.</tspan>
                <tspan x="0" y="187">AKLIEF Cream is for topical use only. Not for oral, ophthalmic, or intravaginal use.</tspan>
            </tspan>
            <tspan x="0" y="206" xml:space="preserve">3   DOSAGE FORMS AND STRENGTHS</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="225" xml:space="preserve">     Cream: 0.005%. Each gram of AKLIEF Cream contains 50 mcg of trifarotene in a white cream.</tspan>
            </tspan>
            <tspan x="0" y="244" xml:space="preserve">4   CONTRAINDICATIONS</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="263" xml:space="preserve">     None</tspan>
            </tspan>
            <tspan x="0" y="282" xml:space="preserve">5   WARNINGS AND PRECAUTIONS</tspan>
            <tspan x="0" y="301" xml:space="preserve">     5.1   Skin Irritation</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="320" xml:space="preserve">     Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Maximum severity of these reactions </tspan>
                <tspan x="0" y="339" xml:space="preserve">     typically occurred within the first 4 weeks of treatment, and severity decreased with continued use of the medication. Depending upon </tspan>
                <tspan x="0" y="358" xml:space="preserve">     the severity of these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of application of AKLIEF Cream, or </tspan>
                <tspan x="0" y="377" xml:space="preserve">     suspend use temporarily. If severe reactions persist the treatment may be discontinued.</tspan>
                <tspan x="0" y="396" xml:space="preserve">     Avoid application of AKLIEF Cream to cuts, abrasions, or eczematous or sunburned skin. Use of “waxing” as a depilatory method should      </tspan>
                <tspan x="0" y="415" xml:space="preserve">     be avoided on skin treated with AKLIEF Cream.</tspan>
            </tspan>
            <tspan x="0" y="434" xml:space="preserve">     5.2   Ultraviolet Light and Environmental Exposure</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="453" xml:space="preserve">     Minimize unprotected exposure to ultraviolet rays (including sunlight and sunlamps) during treatment with AKLIEF Cream. Warn patients </tspan>
                <tspan x="0" y="472" xml:space="preserve">     who normally experience high levels of sun exposure and those with inherent sensitivity to sun to exercise caution. Use of sunscreen </tspan>
                <tspan x="0" y="491" xml:space="preserve">     products and protective clothing over treated areas is recommended when exposure cannot be avoided.</tspan>
            </tspan>
            <tspan x="0" y="510" xml:space="preserve">6   ADVERSE REACTIONS</tspan>
            <tspan x="0" y="529" xml:space="preserve">     6.1   Clinical trials experience</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="548" xml:space="preserve">     Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug </tspan>
                <tspan x="0" y="567" xml:space="preserve">     cannot be directly compared with rates in the clinical trials of another drug and may not reflect rates observed in practice. In the three </tspan>
                <tspan x="0" y="586" xml:space="preserve">     Phase 3 clinical trials, a total of 1673 subjects with acne vulgaris on the face and trunk, 9 years and older were exposed to AKLIEF Cream. </tspan>
                <tspan x="0" y="605" xml:space="preserve">     Of these, 1220 subjects were treated once daily for up to 12 weeks and 453 were treated once daily for up to 1 year.</tspan>
                <tspan x="0" y="624"></tspan>
                <tspan x="0" y="643" xml:space="preserve">     Adverse reactions reported in the 2 randomized, double-blind, vehicle-controlled 12-week clinical trials in ≥1.0% of subjects treated with </tspan>
                <tspan x="0" y="662" xml:space="preserve">     AKLIEF Cream (and for which the rate exceeded the rate for vehicle), as well as the corresponding rates reported in subjects treated with </tspan>
                <tspan x="0" y="681" xml:space="preserve">     the vehicle cream are presented in Table 1.</tspan>
            </tspan>
        </text>
        <text id="Additional_adverse_reactions_that_were_reported_in_more_than_one_subject_treated_with_AKLIEF_Cream_and_at_a_frequency_1_included_application_site_pain_application_site_dryness_application_site_discoloration_application_site_rash_application_site_sw" data-name="Additional adverse reactions that were reported in more than one subject treated with AKLIEF Cream (and at a frequency &lt;1%) included application site pain, application site dryness, application site discoloration, application site rash, application site sw" transform="translate(336 1884)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="0" y="16">Additional adverse reactions that were reported in more than one subject treated with AKLIEF Cream (and at a frequency &lt;1%) included </tspan>
            <tspan x="0" y="35">application site pain, application site dryness, application site discoloration, application site rash, application site swelling, application site </tspan>
            <tspan x="0" y="54">erosion, acne, dermatitis allergic, and erythema.</tspan>
            <tspan x="0" y="73"></tspan>
            <tspan x="0" y="92">In the one-year, open-label safety trial that included 453 subjects 9 years and older, with acne vulgaris of the face and trunk, the pattern of </tspan>
            <tspan x="0" y="111">adverse reactions for AKLIEF Cream was similar to that experienced in the 12-week controlled trials. A total of 12.6% of subjects had at least </tspan>
            <tspan x="0" y="130">one adverse reaction during the trial, and 2.9% of subjects had an adverse reaction leading to treatment discontinuation. The most common </tspan>
            <tspan x="0" y="149">adverse reactions (≥ 1% of subjects) for the entire trial were application site pruritus (4.6%), application site irritation (4.2%), and sunburn </tspan>
            <tspan x="0" y="168">(5.5%). The frequency of adverse reactions decreased over time.</tspan>
            <tspan x="0" y="187"></tspan>
            <tspan x="0" y="206">Skin irritation was evaluated by active assessment of erythema, scaling, dryness, and stinging/burning and collected separately. In the two </tspan>
            <tspan x="0" y="225">12-week Phase 3 clinical trials, these signs/symptoms were assessed at baseline and at least one post-baseline visit, in 1214 subjects (for </tspan>
            <tspan x="0" y="244">face) and 1202 subjects (for trunk) treated with AKLIEF Cream. The percentage of subjects who were assessed to have these signs and </tspan>
            <tspan x="0" y="263">symptoms at any post baseline visit and at a severity worse than baseline are summarized in Table 2.</tspan>
        </text>
        <text id="Local_tolerability_on_the_face_in_subjects_treated_with_AKLIEF_Cream_worsened_for_any_of_the_signs_symptoms_compared_with_baseline_to_a_score_of_moderate_for_up_to_30_of_subjects_or_severe_for_up_to_6_of_subjects._On_the_trunk_the_corresponding_percent" data-name="Local tolerability on the face in subjects treated with AKLIEF Cream worsened for any of the signs/symptoms compared with baseline to a score of moderate for up to 30% of subjects, or severe for up to 6% of subjects. On the trunk, the corresponding percent" transform="translate(336 2582)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="0" y="16">Local tolerability on the face in subjects treated with AKLIEF Cream worsened for any of the signs/symptoms compared with baseline to a </tspan>
            <tspan x="0" y="35">score of moderate for up to 30% of subjects, or severe for up to 6% of subjects. On the trunk, the corresponding percentages were up to 19% </tspan>
            <tspan x="0" y="54">(moderate) and up to 5% (severe). The scores reached maximum severity at Week 1 for the face, and at Week 2 to 4 of treatment for the trunk, </tspan>
            <tspan x="0" y="73">and decreased thereafter.</tspan>
            <tspan x="0" y="92">In the open-label, 1-year Phase 3 trial, the local tolerability profile was comparable to that observed in the two pivotal Phase 3 trials.</tspan>
            <tspan class="sofiapro-bold" font-weight="700">
                <tspan x="0" y="111" xml:space="preserve">7   DRUG INTERACTIONS</tspan>
            </tspan>
            <tspan x="0" y="130">Topical application of AKLIEF Cream is not expected to affect the circulating concentrations of oral hormonal contraceptives containing </tspan>
            <tspan x="0" y="149">ethinyl estradiol and levonorgestrel.</tspan>
            <tspan class="sofiapro-bold" font-weight="700">
                <tspan x="0" y="168" xml:space="preserve">8   USE IN SPECIFIC POPULATIONS</tspan>
                <tspan x="0" y="187" xml:space="preserve">     8.1   Pregnancy</tspan>
            </tspan>
            <tspan x="18" y="206" text-decoration="underline">Risk Summary</tspan>
        </text>
        <text id="Available_data_from_clinical_trials_with_AKLIEF_Cream_use_in_pregnant_women_have_not_identified_a_drug-associated_risk_of_major_birth_defects_miscarriage_or_adverse_maternal_or_fetal_outcomes._There_are_case_reports_of_major_birth_defects_similar_to_thos" data-name="Available data from clinical trials with AKLIEF Cream use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.  There are case reports of major birth defects similar to thos" transform="translate(352 2796)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="0" y="16">Available data from clinical trials with AKLIEF Cream use in pregnant women have not identified a drug-associated risk of major birth </tspan>
            <tspan x="0" y="35" xml:space="preserve">defects, miscarriage or adverse maternal or fetal outcomes.  There are case reports of major birth defects similar to those seen in fetuses </tspan>
            <tspan x="0" y="54">exposed to oral retinoids in pregnant women exposed to other topical retinoids, but these case reports do not establish a pattern or </tspan>
            <tspan x="0" y="73">association with retinoid-related embryopathy.</tspan>
            <tspan x="0" y="92">In animal reproduction studies, oral doses of trifarotene administered to pregnant rats and rabbits during organogenesis that resulted in </tspan>
            <tspan x="0" y="111">systemic exposures more than 800 times the systemic exposure at the maximum recommended human dose (MRHD) of AKLIEF Cream </tspan>
            <tspan x="0" y="130">resulted in adverse fetal effects, including fetal deaths and external, visceral, and skeletal malformations (see Data). The background risk of </tspan>
            <tspan x="0" y="149">major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or </tspan>
            <tspan x="0" y="168">other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically </tspan>
            <tspan x="0" y="187">recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</tspan>
            <tspan text-decoration="underline">
                <tspan x="0" y="206">Data</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Lightitalic, Sofia Pro Condensed" font-style="italic">
                <tspan x="0" y="225">Animal Data</tspan>
            </tspan>
            <tspan x="0" y="244">Oral administration of trifarotene to pregnant rats during the period of organogenesis at doses that resulted in systemic exposures greater </tspan>
            <tspan x="0" y="263">than 1600 times those in humans at the MRHD of AKLIEF Cream resulted in adverse fetal effects, including fetal deaths, reduced mean fetal </tspan>
            <tspan x="0" y="282">weight, and external, visceral, and skeletal malformations.</tspan>
            <tspan x="0" y="301">Oral administration of trifarotene to pregnant rabbits during the period of organogenesis at doses that resulted in systemic exposures at </tspan>
            <tspan x="0" y="320">least 800 times those in humans at the MRHD of AKLIEF Cream resulted in adverse fetal effects, including defects of the tail, limbs, urogenital </tspan>
            <tspan x="0" y="339">organs, and vertebral column.</tspan>
            <tspan x="0" y="358">Trifarotene administered orally to female rats from gestation Day 6 to lactation Day 20, at doses that resulted in systemic exposures up to </tspan>
            <tspan x="0" y="377">594 times those in humans at the MRHD of AKLIEF Cream, had no effect on maternal function or behavior, including gestation, delivery, pup-</tspan>
            <tspan x="0" y="396">rearing, lactation and nursing, or survival or development of pups. There were no effects of maternal treatment on behavior, learning, </tspan>
            <tspan x="0" y="415">memory, or reproductive function of pups.</tspan>
            <tspan class="sofiapro-bold" font-weight="700">
                <tspan x="0" y="434" xml:space="preserve">8.2   Lactation</tspan>
            </tspan>
            <tspan text-decoration="underline">
                <tspan x="0" y="453">Risk Summary</tspan>
            </tspan>
            <tspan x="0" y="472">There are no data on the presence of trifarotene in human milk, the effects on the breastfed infant, or the effects on milk production. In </tspan>
            <tspan x="0" y="491">animal studies, trifarotene was present in rat milk with oral administration of the drug. When a drug is present in animal milk, it is likely that </tspan>
            <tspan x="0" y="510">the drug will be present in human milk. It is possible that topical administration of large amounts of trifarotene could result in sufficient </tspan>
            <tspan x="0" y="529">systemic absorption to produce detectable quantities in human milk (see Clinical Considerations). The developmental and health benefits of </tspan>
            <tspan x="0" y="548">breastfeeding should be considered along with the mother’s clinical need for AKLIEF Cream and any potential adverse effects on the </tspan>
            <tspan x="0" y="567">breastfed infant from AKLIEF Cream or from the underlying maternal condition.</tspan>
            <tspan text-decoration="underline">
                <tspan x="0" y="586">Clinical Considerations</tspan>
            </tspan>
            <tspan x="0" y="605">To minimize potential exposure to the breastfed infant via breastmilk, use AKLIEF Cream on the smallest area of skin and for the shortest </tspan>
            <tspan x="0" y="624">duration possible while breastfeeding. Advise breastfeeding women not to apply AKLIEF Cream directly to the nipple and areola to avoid </tspan>
            <tspan x="0" y="643">direct infant exposure.</tspan>
            <tspan class="sofiapro-bold" font-weight="700">
                <tspan x="0" y="662" xml:space="preserve">8.4   Pediatric Use</tspan>
            </tspan>
            <tspan x="0" y="681">Safety and effectiveness of AKLIEF Cream for the topical treatment of acne vulgaris have been established in pediatric patients age 9 years </tspan>
            <tspan x="0" y="700">to 17 years based on evidence from well-controlled clinical trials, long-term safety trial, and a pharmacokinetic trial. A total of 897 pediatric </tspan>
            <tspan x="0" y="719">subjects aged 9 to 17 years received AKLIEF Cream in the clinical trials [see Clinical Pharmacology (12.3) and Clinical Studies (14)].</tspan>
            <tspan x="0" y="738">Safety and effectiveness of AKLIEF Cream have not been established in pediatric subjects under the age of 9 years.</tspan>
            <tspan class="sofiapro-bold" font-weight="700">
                <tspan x="0" y="757" xml:space="preserve">8.5   Geriatric use</tspan>
            </tspan>
            <tspan x="0" y="776">Clinical trials of AKLIEF Cream did not include any subjects aged 65 years and over to determine whether they respond differently than </tspan>
            <tspan x="0" y="795">younger subjects.</tspan>
        </text>
        <text id="_11_DESCRIPTION_AKLIEF_Cream_for_topical_administration_contains_0.005_50_mcg_g_trifarotene._Trifarotene_is_a_terphenyl_acid_derivative_and_is_a_retinoid._The_chemical_name_of_trifarotene_is_3_-tert-Butyl-4_-_2-hydroxy-ethoxy_-4_-pyrrolidin-1-yl-_1_1_3" data-name="11  DESCRIPTION AKLIEF Cream for topical administration contains 0.005% (50 mcg/g) trifarotene. Trifarotene is a terphenyl acid derivative and is a retinoid. The chemical name of trifarotene is 3”-tert-Butyl-4’-(2-hydroxy-ethoxy)-4”-pyrrolidin-1-yl-[1,1’,3" transform="translate(336 3599)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="0" y="16" xml:space="preserve">11  DESCRIPTION</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="35">AKLIEF Cream for topical administration contains 0.005% (50 mcg/g) </tspan>
                <tspan x="0" y="54">trifarotene. Trifarotene is a terphenyl acid derivative and is a </tspan>
                <tspan x="0" y="73">retinoid. The chemical name of trifarotene is 3”-tert-Butyl-4’-(2-</tspan>
                <tspan x="0" y="92">hydroxy-ethoxy)-4”-pyrrolidin-1-yl-[1,1’,3’,1”]terphenyl-4-carboxylic </tspan>
                <tspan x="0" y="111">acid. Trifarotene has the molecular formula of C29H33NO4, the </tspan>
                <tspan x="0" y="130">molecular weight of 459.58, and the following structural formula:</tspan>
            </tspan>
        </text>
        <text id="Trifarotene_is_a_white_to_off-white_to_slightly_yellow_powder_with_the_melting_point_of_245_C._It_is_practically_insoluble_in_water_with_pKa1_of_5.69_and_pKa2_of_4.55._AKLIEF_trifarotene_Cream_0.005_contains_the_following_inactive_ingredients:_allantoin" data-name="Trifarotene is a white to off-white to slightly yellow powder with the melting point of 245°C. It is practically insoluble in water with pKa1 of 5.69 and pKa2 of 4.55. AKLIEF (trifarotene) Cream 0.005% contains the following inactive ingredients: allantoin" transform="translate(336 3742)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="0" y="16">Trifarotene is a white to off-white to slightly yellow powder with the melting point of 245°C. It is practically insoluble in water with pKa1 of 5.69 </tspan>
            <tspan x="0" y="35">and pKa2 of 4.55. AKLIEF (trifarotene) Cream 0.005% contains the following inactive ingredients: allantoin, copolymer of acrylamide and </tspan>
            <tspan x="0" y="54">sodium acryloyldimethyltaurate, dispersion 40% in isohexadecane, cyclomethicone, 5% ethanol, medium-chain triglycerides, </tspan>
            <tspan x="0" y="73">phenoxyethanol, propylene glycol, purified water.</tspan>
            <tspan class="sofiapro-bold" font-weight="700">
                <tspan x="0" y="94" xml:space="preserve">12  CLINICAL PHARMACOLOGY</tspan>
            </tspan>
        </text>
        <text id="_13.1_Carcinogenesis_Mutagenesis_Impairment_of_Fertility_Trifarotene_was_not_carcinogenic_when_topically_applied_to_mice_daily_for_up_to_24_months_in_the_vehicle_of_the_product_AKLIEF_Cream_at_concentrations_of_0.0005_or_0.001_w_w._The_systemic_expo" data-name="13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility Trifarotene was not carcinogenic when topically applied to mice daily for up to 24 months in the vehicle of the product (AKLIEF Cream) at concentrations of 0.0005% or 0.001% w/w. The systemic expo" transform="translate(352 4512)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="0" y="16" xml:space="preserve">13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="37">Trifarotene was not carcinogenic when topically applied to mice daily for up to 24 months in the vehicle of the product (AKLIEF Cream) at </tspan>
                <tspan x="0" y="56">concentrations of 0.0005% or 0.001% w/w. The systemic exposures at the highest doses evaluated in mice were approximately 82 (males) and </tspan>
                <tspan x="0" y="75">99 (females) times higher than the human exposure at the MRHD of AKLIEF Cream.</tspan>
                <tspan x="0" y="96">Trifarotene was not carcinogenic when administered orally to rats daily for up to 24 months at doses up to 0.75 mg/kg/day in males and 0.2 </tspan>
                <tspan x="0" y="115">mg/kg/day in females. The systemic exposures at the highest doses evaluated in rats were approximately 645 (males) and 1642 (females) </tspan>
                <tspan x="0" y="134">times higher than the human exposure at the MRHD of AKLIEF Cream.</tspan>
                <tspan x="0" y="155">Trifarotene was negative in an in vitro bacterial reverse mutation (Ames) assay, an in vitro micronucleus assay in primary human </tspan>
                <tspan x="0" y="174">lymphocytes, an in vitro mouse lymphoma assay with L5178Y/TK+/- cells, and an in vivo micronucleus assay in rats.</tspan>
                <tspan x="0" y="195">Trifarotene was assessed for effects on fertility or general reproductive function in rats. Males received trifarotene via oral gavage for 4 </tspan>
                <tspan x="0" y="214">weeks prior to mating, during mating, and up to scheduled termination (approximately 6 weeks in total), and females were treated via oral </tspan>
                <tspan x="0" y="233">gavage for 2 weeks prior to mating through Day 7 of gestation. No adverse effects on fertility or reproductive parameters, including sperm </tspan>
                <tspan x="0" y="252">motility and concentration, were observed at the highest doses evaluated, which resulted in systemic exposures approximately 1755 (males) </tspan>
                <tspan x="0" y="271">and 1726 (females) times higher than the human exposure at the MRHD of AKLIEF Cream.</tspan>
            </tspan>
        </text>
        <text id="_14_CLINICAL_STUDIES" data-name="14  CLINICAL STUDIES" transform="translate(336 4788)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="0" y="16" xml:space="preserve">14  CLINICAL STUDIES</tspan>
        </text>
        <text id="AKLIEF_Cream_applied_once_daily_in_the_evening_was_evaluated_in_the_treatment_of_moderate_facial_and_truncal_acne_vulgaris_in_two_randomized_multicenter_parallel_group_double-blind_vehicle-controlled_trials_of_identical_design_Study_1_NCT02566369_an" data-name="AKLIEF Cream applied once daily in the evening was evaluated in the treatment of moderate facial and truncal acne vulgaris in two randomized, multicenter, parallel group, double-blind, vehicle-controlled trials of identical design, Study 1 (NCT02566369) an" transform="translate(352 4810)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="0" y="16">AKLIEF Cream applied once daily in the evening was evaluated in the treatment of moderate facial and truncal acne vulgaris in two </tspan>
            <tspan x="0" y="35">randomized, multicenter, parallel group, double-blind, vehicle-controlled trials of identical design, Study 1 (NCT02566369) and Study 2 </tspan>
            <tspan x="0" y="54">(NCT02556788). The trials were conducted in a total of 2420 subjects aged 9 years and older, who were treated for up to 12 weeks with either </tspan>
            <tspan x="0" y="73">AKLIEF Cream (1214 subjects) or vehicle cream (1206 subjects). Subjects were encouraged to use a moisturizer as desired, while allowing an </tspan>
            <tspan x="0" y="92">interval of approximately 1 hour before or after the study treatment application.</tspan>
            <tspan x="0" y="113">Acne severity was evaluated using a 5-point Investigator’s Global Assessment (IGA) scale for the face and a 5-point Physician’s Global </tspan>
            <tspan x="0" y="132">Assessment (PGA) scale for the trunk with moderate acne vulgaris defined as a score of 3. Overall, 87% of subjects were Caucasian and 55% </tspan>
            <tspan x="0" y="151">were female. Thirty-four (1.4%) subjects were 9 to 11 years of age, 1128 (47%) subjects were 12 to 17 years of age, and 1258 (52%) subjects were </tspan>
            <tspan x="0" y="170">18 years and older. All subjects had moderate acne vulgaris on the face and 99% of subjects had moderate acne vulgaris on the trunk. At </tspan>
            <tspan x="0" y="189">baseline, subjects had between 7 and 200 (average 36) inflammatory lesions on the face and between 0 and 220 (average 38) on the trunk. </tspan>
            <tspan x="0" y="208">Additionally, subjects had 21 to 305 (average 52) non-inflammatory lesions on the face and 0 to 260 (average 46) on the trunk.</tspan>
            <tspan x="0" y="229">Success on the IGA/PGA scale was defined as achieving a score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from </tspan>
            <tspan x="0" y="248">baseline. The co-primary endpoints (evaluated on the face) were the percentage of subjects achieving success on the IGA scale, the mean </tspan>
            <tspan x="0" y="267">absolute change in facial inflammatory lesion count from baseline, and the mean absolute change in facial non-inflammatory lesion count </tspan>
            <tspan x="0" y="286">from baseline, all evaluated at Week 12. The co-secondary endpoints (evaluated on the trunk) were the percentage of subjects achieving </tspan>
            <tspan x="0" y="305">success on the PGA scale, the mean absolute change in truncal inflammatory lesion count from baseline, and the mean absolute change in </tspan>
            <tspan x="0" y="324">truncal non-inflammatory lesion count from baseline, all evaluated at Week 12. Efficacy results for acne on the face and trunk after 12 weeks </tspan>
            <tspan x="0" y="343">of treatment are presented in Tables 3 and 4 respectively.</tspan>
        </text>
        <text id="_13_NONCLINICAL_TOXICOLOGY" data-name="13  NONCLINICAL TOXICOLOGY" transform="translate(336 4492)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="0" y="16" xml:space="preserve">13  NONCLINICAL TOXICOLOGY</tspan>
        </text>
        <text id="_12.1_Mechanism_of_Action_Trifarotene_is_an_agonist_of_retinoic_acid_receptors_RAR_with_particular_activity_at_the_gamma_subtype_of_RAR._Stimulation_of_RAR_results_in_modulation_of_target_genes_which_are_associated_with_various_processes_including_cel" data-name="12.1   Mechanism of Action Trifarotene is an agonist of retinoic acid receptors (RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results in modulation of target genes which are associated with various processes, including cel" transform="translate(352 3842)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="0" y="16" xml:space="preserve">12.1   Mechanism of Action</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="35">Trifarotene is an agonist of retinoic acid receptors (RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results </tspan>
                <tspan x="0" y="54">in modulation of target genes which are associated with various processes, including cell differentiation and mediation of inflammation. </tspan>
                <tspan x="0" y="73">The exact process by which trifarotene ameliorates acne is unknown.</tspan>
            </tspan>
            <tspan x="0" y="92" xml:space="preserve">12.2   Pharmacodynamics</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="111">At the approved recommended dosage, AKLIEF Cream does not prolong the QT interval to any clinically relevant extent.</tspan>
            </tspan>
            <tspan x="0" y="130" xml:space="preserve">12.3   Pharmacokinetics</tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="149">Pharmacokinetics of trifarotene was evaluated in a study involving 19 adult subjects with acne vulgaris following once daily application of </tspan>
                <tspan x="0" y="168">AKLIEF Cream for 29 days (daily dose range 1.5 g/day to 2 g/day) to the face, shoulders, chest and upper back.</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300" text-decoration="underline">
                <tspan x="0" y="187">Absorption</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="206">Systemic concentrations were at steady state following 2 weeks of treatment and were quantifiable in 7 subjects. Steady state Cmax </tspan>
                <tspan x="0" y="225">ranged from below the limit of quantification (less than 5 pg/mL) to 10 pg/mL and AUC0-24h ranged from 75 to 104 pg.h/mL in adults. No </tspan>
                <tspan x="0" y="244">drug accumulation is expected with long-term use.</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300" text-decoration="underline">
                <tspan x="0" y="263">Distribution</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="282">Plasma protein binding is approximately 99.9%.</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300" text-decoration="underline">
                <tspan x="0" y="301">Elimination</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="320">The terminal half-life ranged from 2 to 9 hours.</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Lightitalic, Sofia Pro Condensed" font-weight="300" font-style="italic">
                <tspan x="0" y="339">Metabolism</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="358">Trifarotene is primarily metabolized by CYP2C9, CYP3A4, CYP2C8, and to a lesser extent by CYP2B6 in vitro.</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Lightitalic, Sofia Pro Condensed" font-weight="300" font-style="italic">
                <tspan x="0" y="377">Excretion</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="396">Trifarotene is primarily excreted by the feces.</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300" text-decoration="underline">
                <tspan x="0" y="415">Specific Populations</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Lightitalic, Sofia Pro Condensed" font-weight="300" font-style="italic">
                <tspan x="0" y="434">Pediatric Patients</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="453">Steady state Cmax ranged from less than 5 pg/mL to 9 pg/mL and AUC0-24h ranged from 89 to 106 pg.h/mL in pediatrics (10 to 17-years-</tspan>
                <tspan x="0" y="472">old). Steady state conditions were achieved in patients following 2 weeks of topical administration. No drug accumulation is expected </tspan>
                <tspan x="0" y="491">with long-term use.</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300" text-decoration="underline">
                <tspan x="0" y="510">Drug Interactions Studies</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Lightitalic, Sofia Pro Condensed" font-weight="300" font-style="italic">
                <tspan x="0" y="529">Clinical Studies and Model-Based Approaches</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="0" y="548">No clinically significant differences in the pharmacokinetics of trifarotene were predicted when used concomitantly with fluconazole (a </tspan>
                <tspan x="0" y="567">moderate CYP2C9 and CYP3A inhibitor).</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Lightitalic, Sofia Pro Condensed" font-weight="300" font-style="italic">
                <tspan x="0" y="586">In Vitro Studies</tspan>
                <tspan x="0" y="605">Cytochrome P450 (CYP) Enzymes:</tspan>
                <tspan y="605" xml:space="preserve" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-style="normal"> AKLIEF Cream is not expected to inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4, or induce CYP1A2, </tspan>
                <tspan x="0" y="624" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-style="normal">2B6, and 3A4.</tspan>
                <tspan x="0" y="643">Transporter Systems: </tspan>
                <tspan y="643" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-style="normal">AKLIEF Cream is not expected to inhibit MATE, OATP, OAT, OCT, BCRP, P-gp, BSEP, or MPR.</tspan>
            </tspan>
        </text>
        <text id="_16_HOW_SUPPLIED_STORAGE_AND_HANDLING" data-name="16  HOW SUPPLIED/STORAGE AND HANDLING" transform="translate(336 5857)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="0" y="16" xml:space="preserve">16  HOW SUPPLIED/STORAGE AND HANDLING</tspan>
        </text>
        <text id="AKLIEF_Cream_0.005_is_provided_as_a_white_cream_supplied_in_the_following_packaging_configurations_with_corresponding_NDC_numbers:_30-gram_pump_NDC_0299-5935-30_45-gram_pump_NDC_0299-5935-45_75-gram_pump_NDC_0299-5935-75_Storage_and_Handling_" data-name="AKLIEF Cream, 0.005% is provided as a white cream supplied in the following packaging configurations with corresponding NDC numbers: •   30-gram pump    NDC 0299-5935-30 •   45-gram pump    NDC 0299-5935-45 •   75-gram pump    NDC 0299-5935-75 Storage and Handling" transform="translate(352 5878)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="0" y="16">AKLIEF Cream, 0.005% is provided as a white cream supplied in the following packaging configurations with corresponding NDC numbers:</tspan>
            <tspan x="0" y="35" xml:space="preserve">•   30-gram pump NDC 0299-5935-30</tspan>
            <tspan x="0" y="54" xml:space="preserve">•   45-gram pump   NDC 0299-5935-45</tspan>
            <tspan x="0" y="73" xml:space="preserve">•   75-gram pump   NDC 0299-5935-75</tspan>
            <tspan text-decoration="underline">
                <tspan x="0" y="92">Storage and Handling</tspan>
            </tspan>
            <tspan x="0" y="111">- Store at 20 to 25˚C (68 to 77˚F) with excursions permitted to 15°to 30°C (59° to 86°F).</tspan>
            <tspan x="0" y="130">- Keep away from heat.</tspan>
            <tspan x="0" y="149">- Keep out of reach of children.</tspan>
        </text>
        <text id="See_FDA-approved_patient_labeling_Patient_Information_._Advise_the_patient_to:_Cleanse_the_area_to_be_treated_pat_dry._Apply_AKLIEF_Cream_as_a_thin_layer_once_daily_in_the_evening_to_the_face_avoiding_the_eyes_lips_nasolabial_folds_and_m" data-name="See FDA-approved patient labeling (Patient Information). Advise the patient to: •   Cleanse the area to be treated; pat dry. Apply AKLIEF Cream as a thin layer once daily in the evening to the face, avoiding the eyes, lips, nasolabial folds, and m" transform="translate(352 6054)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="0" y="16">See FDA-approved patient labeling (Patient Information).</tspan>
            <tspan x="0" y="35">Advise the patient to:</tspan>
            <tspan x="0" y="54" xml:space="preserve">•   Cleanse the area to be treated; pat dry. Apply AKLIEF Cream as a thin layer once daily in the evening to the face, avoiding the eyes, lips,    </tspan>
            <tspan x="0" y="73" xml:space="preserve">     nasolabial folds, and mucous membranes. A thin layer of AKLIEF Cream may also be applied to the chest, shoulders, and back.</tspan>
            <tspan x="0" y="92" xml:space="preserve">•   Avoid applying AKLIEF Cream to damaged skin (such as cuts, abrasions), eczematous areas, and sunburned skin.</tspan>
            <tspan x="0" y="111" xml:space="preserve">•   Reduce the risk of such irritation, use a moisturizer from the start of treatment, and, if appropriate, reduce the frequency of application of </tspan>
            <tspan x="0" y="130" xml:space="preserve">     AKLIEF Cream or suspend use temporarily. AKLIEF Cream may cause irritation such as erythema, scaling, dryness, and stinging or </tspan>
            <tspan x="0" y="149" xml:space="preserve">     burning.</tspan>
            <tspan x="0" y="168" xml:space="preserve">•   Minimize exposure to sunlight, including sunlamps and phototherapy devices.</tspan>
            <tspan x="0" y="187" xml:space="preserve">•   Use sunscreen products and protective apparel (e.g., hat) over treated areas when exposure to sunlight cannot be avoided.</tspan>
            <tspan x="0" y="206" xml:space="preserve">•   Avoid concomitant use of other potentially irritating topical products (medicated or not).</tspan>
            <tspan x="0" y="225" xml:space="preserve">•   Use AKLIEF Cream on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women </tspan>
            <tspan x="0" y="244" xml:space="preserve">     not to apply AKLIEF Cream directly to the nipple and areola to avoid direct infant exposure.</tspan>
        </text>
        <text id="_17_PATIENT_COUNSELING_INFORMATION" data-name="17  PATIENT COUNSELING INFORMATION" transform="translate(336 6034)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="0" y="16" xml:space="preserve">17  PATIENT COUNSELING INFORMATION</tspan>
        </text>
        <text id="FULL_PRESCRIBING_INFORMATION:_CONTENTS_" data-name="FULL PRESCRIBING INFORMATION: CONTENTS*" transform="translate(578 615)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="84.016" y="16">FULL PRESCRIBING INFORMATION: CONTENTS*</tspan>
        </text>
        <text id="FULL_PRESCRIBING_INFORMATION" data-name="FULL PRESCRIBING INFORMATION" transform="translate(504 981)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="120.496" y="16">FULL PRESCRIBING INFORMATION</tspan>
        </text>
        <g id="Group_15" data-name="Group 15">
            <g id="Group_1" data-name="Group 1" transform="translate(336 1759.623)">
                <rect id="Rectangle_1" data-name="Rectangle 1" width="1000" height="107.721" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
                <line id="Line_1" data-name="Line 1" x2="1000" transform="translate(0 80.791)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
                <line id="Line_2" data-name="Line 2" x2="1000" transform="translate(0 53.861)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
                <line id="Line_3" data-name="Line 3" x2="1000" transform="translate(0 26.93)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
                <line id="Line_4" data-name="Line 4" y2="107.721" transform="translate(350)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
                <line id="Line_5" data-name="Line 5" y2="107.721" transform="translate(644)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
            </g>
            <text id="Preferred_Term_Application_site_irritation_Application_site_pruritus_Sunburn" data-name="Preferred Term Application site irritation Application site pruritus Sunburn" transform="translate(374 1763.335)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
                <tspan x="45.847" y="16">Preferred Term</tspan>
                <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                    <tspan x="21.623" y="42">Application site irritation</tspan>
                    <tspan x="23.567" y="68">Application site pruritus</tspan>
                    <tspan x="65.215" y="94">Sunburn</tspan>
                </tspan>
            </text>
            <text id="AKLIEF_Cream_N_1220_91_7.5_29_2.4_32_2.6_" data-name="AKLIEF Cream (N= 1220) 91 (7.5) 29 (2.4) 32 (2.6)" transform="translate(726.548 1763.335)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
                <tspan x="21.578" y="16">AKLIEF Cream (N= 1220)</tspan>
                <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                    <tspan x="70.898" y="42">91 (7.5)</tspan>
                    <tspan x="69.402" y="68">29 (2.4)</tspan>
                    <tspan x="69.77" y="94">32 (2.6)</tspan>
                </tspan>
            </text>
            <text id="Vehicle_Cream_N_1200_4_0.3_10_0.8_6_0.5_" data-name="Vehicle Cream (N=1200) 4 (0.3) 10 (0.8) 6 (0.5)" transform="translate(1041 1763.335)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
                <tspan x="21.175" y="16">Vehicle Cream (N=1200)</tspan>
                <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                    <tspan x="72.023" y="42">4 (0.3)</tspan>
                    <tspan x="69.519" y="68">10 (0.8)</tspan>
                    <tspan x="71.615" y="94">6 (0.5)</tspan>
                </tspan>
            </text>
            <text id="Table_1._Adverse_Reactions_Occurring_in_1.0_of_Subjects_with_Acne_Vulgaris_of_the_Face_and_Trunk_in_the_Two_12-week_Phase_3_Clinical_Trials" data-name="Table 1. Adverse Reactions Occurring in ≥ 1.0% of Subjects with Acne Vulgaris of the Face and Trunk in the Two 12-week Phase 3 Clinical Trials" transform="translate(336 1706)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
                <tspan x="0" y="16">Table 1. Adverse Reactions Occurring in ≥ 1.0% of Subjects with Acne Vulgaris of the Face </tspan>
                <tspan x="0" y="35">and Trunk in the Two 12-week Phase 3 Clinical Trials</tspan>
            </text>
        </g>
        <text id="Table_2._Application_Site_Tolerability_Reactions_at_Any_Post_Baseline_Visit" data-name="Table 2. Application Site Tolerability Reactions at Any Post Baseline Visit" transform="translate(336 2165.074)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700" letter-spacing="-0.01em">
            <tspan x="0" y="16">Table 2. Application Site Tolerability Reactions at Any Post Baseline Visit</tspan>
        </text>
        <text id="Erythema_Scaling_Dryness_" data-name="Erythema Scaling Dryness" transform="translate(338 2275.477)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="18.407" y="16">Erythema</tspan>
            <tspan x="24.759" y="41">Scaling</tspan>
            <tspan x="22.799" y="66">Dryness</tspan>
        </text>
        <text id="Stinging_Burning" data-name="Stinging/Burning" transform="translate(338 2350.477)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="19.583" y="16">Stinging/</tspan>
            <tspan x="23.183" y="35">Burning</tspan>
        </text>
        <text id="Stinging_Burning-2" data-name="Stinging/Burning" transform="translate(338 2505.477)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="19.583" y="16">Stinging/</tspan>
            <tspan x="23.183" y="35">Burning</tspan>
        </text>
        <text id="AKLIEF_Cream_N_1214_Maximum_Severity_during_Treatment" data-name="AKLIEF Cream N=1214 Maximum Severity during Treatment" transform="translate(472.775 2201)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="101.002" y="16">AKLIEF Cream N=1214</tspan>
            <tspan x="58.794" y="35">Maximum Severity during Treatment</tspan>
        </text>
        <text id="Face" transform="translate(341.775 2214)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="28.382" y="16">Face</tspan>
        </text>
        <text id="Vehicle_Cream_N_1194_Maximum_Severity_during_Treatment_" data-name="Vehicle Cream N=1194 Maximum Severity during Treatment " transform="translate(957.675 2201)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="79.366" y="16">Vehicle Cream N=1194</tspan>
            <tspan x="38.294" y="35">Maximum Severity during Treatment</tspan>
        </text>
        <text id="Trunk" transform="translate(355 2401)" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="11.941" y="16">Trunk</tspan>
        </text>
        <text id="N_1202" data-name="N=1202" transform="translate(605.775 2401)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="33.126" y="16">N=1202</tspan>
        </text>
        <text id="N_1185" data-name="N=1185" transform="translate(1075 2401)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="33.598" y="16">N=1185</tspan>
        </text>
        <text id="Erythema_Scaling_Dryness" data-name="Erythema Scaling Dryness" transform="translate(350 2428)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="6.478" y="16">Erythema</tspan>
            <tspan x="12.83" y="42.5">Scaling</tspan>
            <tspan x="10.87" y="69">Dryness</tspan>
        </text>
        <text id="_26.5_29.7_32.9_26.1_" data-name="26.5% 29.7% 32.9% 26.1%" transform="translate(477.231 2430)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="35.031" y="16">26.5%</tspan>
            <tspan x="35.647" y="40.5">29.7%</tspan>
            <tspan x="35.215" y="65">32.9%</tspan>
            <tspan x="36.639" y="89.5">26.1%</tspan>
        </text>
        <text id="_18.9_13.7_16.1_10.9_" data-name="18.9% 13.7% 16.1% 10.9% " transform="translate(611.408 2430)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="34.663" y="16">18.9%</tspan>
            <tspan x="35.423" y="40.5">13.7%</tspan>
            <tspan x="36.327" y="65">16.1%</tspan>
            <tspan x="34.711" y="89.5">10.9%</tspan>
        </text>
        <text id="_5.2_1.7_1.8_4.3_" data-name="5.2% 1.7% 1.8% 4.3% " transform="translate(775.113 2430)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="26.207" y="16">5.2%</tspan>
            <tspan x="27.591" y="40.5">1.7%</tspan>
            <tspan x="27.111" y="65">1.8%</tspan>
            <tspan x="26.071" y="89.5">4.3%</tspan>
            <tspan x="37.887" y="114"></tspan>
        </text>
        <text id="_12.7_13.2_17.8_9.2_" data-name="12.7% 13.2% 17.8% 9.2% " transform="translate(928.817 2430)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="21.495" y="16">12.7%</tspan>
            <tspan x="21.327" y="40.5">13.2%</tspan>
            <tspan x="21.703" y="65">17.8%</tspan>
            <tspan x="23.375" y="89.5">9.2%</tspan>
        </text>
        <text id="_4.4_2.6_3.9_2.2_" data-name="4.4% 2.6% 3.9% 2.2%" transform="translate(1085.45 2430)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="25.777" y="16">4.4%</tspan>
            <tspan x="26.209" y="40.5">2.6%</tspan>
            <tspan x="25.993" y="65">3.9%</tspan>
            <tspan x="26.465" y="89.5">2.2%</tspan>
            <tspan x="37.817" y="114"></tspan>
        </text>
        <text id="_0.4_0.1_0.1_0.5_" data-name="0.4% 0.1% 0.1% 0.5%" transform="translate(1244.225 2430)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="26.903" y="16">0.4%</tspan>
            <tspan x="28.527" y="40.5">0.1%</tspan>
            <tspan x="28.527" y="65">0.1%</tspan>
            <tspan x="26.919" y="89.5">0.5%</tspan>
            <tspan x="38.887" y="114"></tspan>
        </text>
        <text id="Mild_30.6_37.5_39_35.6_" data-name="Mild 30.6% 37.5% 39% 35.6%" transform="translate(489.231 2251)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan fill="#000">
                <tspan x="23.567" y="16">Mild</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="21.047" y="40.5">30.6%</tspan>
                <tspan x="22.039" y="65">37.5%</tspan>
                <tspan x="25.615" y="89.5">39%</tspan>
                <tspan x="21.007" y="114">35.6%</tspan>
            </tspan>
        </text>
        <text id="Moderate_28.4_27.1_29.7_20.6_" data-name="Moderate 28.4% 27.1% 29.7% 20.6%" transform="translate(624.408 2251)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan fill="#000">
                <tspan x="7.999" y="16">Moderate</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="20.775" y="40.5">28.4%</tspan>
                <tspan x="23.407" y="65">27.1%</tspan>
                <tspan x="21.375" y="89.5">29.7%</tspan>
                <tspan x="20.895" y="114">20.6%</tspan>
            </tspan>
        </text>   
        <text id="Severe_6.2_4.9_4.8_5.9_" data-name="Severe 6.2%4.9%4.8%5.9%" transform="translate(775.113 2251)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan fill="#000">
                <tspan x="19.471" y="16">Severe</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="27.183" y="40.5">6.2%</tspan>
                <tspan x="26.791" y="65">4.9%</tspan>
                <tspan x="26.807" y="89.5">4.8%</tspan>
                <tspan x="26.807" y="114">5.9%</tspan>
            </tspan>
        </text>
        <text id="Mild_21_23.7_29.9_15.9_" data-name="Mild 21%23.7%29.9%15.9%" transform="translate(928.817 2251)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan fill="#000">
                <tspan x="21.295" y="16">Mild </tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="24.823" y="40.5">21%</tspan>
                <tspan x="19.463" y="65">23.7%</tspan>
                <tspan x="18.879" y="89.5">29.9%</tspan>
                <tspan x="19.671" y="114">15.9%</tspan>
            </tspan>
        </text>
        <text id="Moderate_6.8_5.9_6.8_3.8_" data-name="Moderate  6.8% 5.9% 6.8% 3.8%" transform="translate(1085.45 2251)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan fill="#000">
                <tspan x="9.999" y="16">Moderate </tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="25.799" y="40.5">6.8%</tspan>
                <tspan x="25.807" y="65">5.9%</tspan>
                <tspan x="25.799" y="89.5">6.8%</tspan>
                <tspan x="26.079" y="114">3.8%</tspan>
                <tspan x="37.887" y="138.5"></tspan>
            </tspan>
        </text>
        <text id="Severe_0.8_0.3_0.8_0.5_" data-name="Severe 0.8% 0.3% 0.8% 0.5%" transform="translate(1244.225 2251)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan fill="#000">
                <tspan x="19.971" y="16">Severe</tspan>
            </tspan>
            <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="27.363" y="40.5">0.8%</tspan>
                <tspan x="27.627" y="65">0.3%</tspan>
                <tspan x="27.363" y="89.5">0.8%</tspan>
                <tspan x="27.419" y="114">0.5%</tspan>
                <tspan x="39.387" y="138.5"></tspan>
            </tspan>
        </text>
        <g id="Group_8" data-name="Group 8" transform="translate(400 50.552)">
            <g id="Group_7" data-name="Group 7" transform="translate(685 3565)">
                <path id="Path_1" data-name="Path 1" d="M1579.236,217.91v-8.536h1.158l4.484,6.7v-6.7h1.082v8.536H1584.8l-4.483-6.708v6.708Z" transform="translate(-1561.508 -179.45)" fill="#1a1818" fill-rule="evenodd"/>
                <path id="Path_2" data-name="Path 2" d="M1596.794,236.306a3.406,3.406,0,0,0,.83,2.431,2.9,2.9,0,0,0,4.182-.007,3.631,3.631,0,0,0,.823-2.545,4.353,4.353,0,0,0-.353-1.82,2.688,2.688,0,0,0-1.032-1.205,2.767,2.767,0,0,0-1.523-.428,2.881,2.881,0,0,0-2.061.823A3.673,3.673,0,0,0,1596.794,236.306Zm-1.166-.016a4.637,4.637,0,0,1,1.143-3.329,3.878,3.878,0,0,1,2.947-1.2,4.1,4.1,0,0,1,2.13.565,3.691,3.691,0,0,1,1.447,1.575,5.1,5.1,0,0,1,.5,2.29,5.036,5.036,0,0,1-.523,2.326,3.594,3.594,0,0,1-1.487,1.552,4.251,4.251,0,0,1-2.071.526,4.039,4.039,0,0,1-2.156-.581,3.766,3.766,0,0,1-1.437-1.591A4.808,4.808,0,0,1,1595.628,236.29Z" transform="translate(-1524.35 -128.707)" fill="#1a1818" fill-rule="evenodd"/>
                <path id="Path_3" data-name="Path 3" d="M1586.016,233.194a3.409,3.409,0,0,0,.833,2.43,2.9,2.9,0,0,0,4.182-.007,3.628,3.628,0,0,0,.82-2.545,4.355,4.355,0,0,0-.35-1.82,2.686,2.686,0,0,0-1.032-1.205,2.774,2.774,0,0,0-1.522-.428,2.891,2.891,0,0,0-2.064.823A3.683,3.683,0,0,0,1586.016,233.194Zm-1.163-.016a4.656,4.656,0,0,1,1.14-3.329,3.886,3.886,0,0,1,2.947-1.2,4.1,4.1,0,0,1,2.133.565,3.707,3.707,0,0,1,1.447,1.575,5.14,5.14,0,0,1,.5,2.29,5.079,5.079,0,0,1-.523,2.326,3.594,3.594,0,0,1-1.487,1.552,4.254,4.254,0,0,1-2.074.526,4.035,4.035,0,0,1-2.153-.582,3.741,3.741,0,0,1-1.437-1.591A4.8,4.8,0,0,1,1584.854,233.178Zm-8.49,4.155V228.8h1.13v3.505h4.436V228.8h1.13v8.533h-1.13v-4.021h-4.436v4.021Z" transform="translate(-1568.019 -135.762)" fill="#1a1818" fill-rule="evenodd"/>
                <path id="Path_4" data-name="Path 4" d="M1649.673,221.226v-8.539h1.131v3.508h4.433v-3.508h1.131v8.539h-1.131V217.2H1650.8v4.025Zm-8.771-4.142a3.425,3.425,0,0,0,.836,2.431,2.888,2.888,0,0,0,4.174-.007,3.612,3.612,0,0,0,.824-2.545,4.212,4.212,0,0,0-.356-1.82,2.724,2.724,0,0,0-1.019-1.205,2.968,2.968,0,0,0-3.587.4A3.673,3.673,0,0,0,1640.9,217.083Zm-1.167-.016a4.637,4.637,0,0,1,1.144-3.329,3.886,3.886,0,0,1,2.946-1.2,4.127,4.127,0,0,1,2.136.565,3.69,3.69,0,0,1,1.438,1.575,5.106,5.106,0,0,1,.5,2.29,4.961,4.961,0,0,1-.526,2.326,3.52,3.52,0,0,1-1.486,1.552,4.237,4.237,0,0,1-2.064.526,4.061,4.061,0,0,1-2.163-.582,3.851,3.851,0,0,1-1.437-1.591A4.938,4.938,0,0,1,1639.735,217.067Z" transform="translate(-1424.367 -172.281)" fill="#1a1818" fill-rule="evenodd"/>
                <path id="Path_5" data-name="Path 5" d="M1635.386,207.521a3.424,3.424,0,0,0,.836,2.43,2.885,2.885,0,0,0,4.175-.01,3.586,3.586,0,0,0,.823-2.542,4.361,4.361,0,0,0-.343-1.82,2.731,2.731,0,0,0-2.555-1.633,2.9,2.9,0,0,0-2.064.823A3.684,3.684,0,0,0,1635.386,207.521Zm-1.166-.016a4.639,4.639,0,0,1,1.143-3.329,3.889,3.889,0,0,1,2.947-1.2,4.147,4.147,0,0,1,2.139.565,3.73,3.73,0,0,1,1.447,1.575,5.1,5.1,0,0,1,.493,2.293,4.952,4.952,0,0,1-.529,2.323,3.521,3.521,0,0,1-1.473,1.548,4.291,4.291,0,0,1-2.077.529,4.071,4.071,0,0,1-2.16-.581,3.806,3.806,0,0,1-1.437-1.591A4.906,4.906,0,0,1,1634.22,207.505Z" transform="translate(-1436.871 -193.956)" fill="#1a1818" fill-rule="evenodd"/>
                <line id="Line_26" data-name="Line 26" y1="10.85" x2="7.094" transform="translate(25.528 16.38)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_27" data-name="Line 27" x1="13.158" y1="16.38" transform="translate(19.464 0)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_28" data-name="Line 28" x1="19.464" y2="7.436" transform="translate(0 0)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_29" data-name="Line 29" x2="1.049" y2="20.849" transform="translate(0 7.436)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_30" data-name="Line 30" x2="13.262" y2="3.61" transform="translate(1.05 28.284)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_31" data-name="Line 31" x1="0.038" y2="20.825" transform="translate(39.292 44.214)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_32" data-name="Line 32" x1="0.029" y2="16.499" transform="translate(43.044 46.369)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_33" data-name="Line 33" x2="18.013" y2="10.319" transform="translate(39.292 65.039)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_34" data-name="Line 34" y1="10.201" x2="18.198" transform="translate(57.304 65.157)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_35" data-name="Line 35" y1="8.078" x2="14.414" transform="translate(57.324 62.963)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_36" data-name="Line 36" x1="0.092" y1="20.926" transform="translate(75.41 44.231)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_37" data-name="Line 37" x1="18.164" y1="10.466" transform="translate(57.247 33.765)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_38" data-name="Line 38" x1="14.389" y1="8.291" transform="translate(57.258 38.127)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_39" data-name="Line 39" x1="17.917" y2="10.449" transform="translate(39.33 33.765)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_40" data-name="Line 40" x1="11.108" y1="6.407" transform="translate(28.222 37.807)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_41" data-name="Line 41" x1="18.011" y2="10.557" transform="translate(21.281 65.039)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_42" data-name="Line 42" x1="17.99" y2="10.557" transform="translate(3.291 75.596)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_43" data-name="Line 43" x2="10.554" y2="17.938" transform="translate(21.281 75.596)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_44" data-name="Line 44" x1="10.588" y1="17.977" transform="translate(10.693 57.619)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_45" data-name="Line 45" x2="17.887" y2="10.406" transform="translate(75.503 65.157)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_46" data-name="Line 46" x1="0.037" y2="20.824" transform="translate(147.335 44.286)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_47" data-name="Line 47" x1="0.037" y2="16.475" transform="translate(151.081 46.449)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_48" data-name="Line 48" x2="18.277" y2="10.32" transform="translate(147.335 65.11)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_49" data-name="Line 49" y1="10.335" x2="17.933" transform="translate(165.612 65.096)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_50" data-name="Line 50" y1="8.194" x2="14.211" transform="translate(165.599 62.947)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_51" data-name="Line 51" x1="0.086" y1="20.927" transform="translate(183.458 44.168)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_52" data-name="Line 52" x1="18.031" y1="10.332" transform="translate(165.428 33.836)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_53" data-name="Line 53" x1="14.297" y1="8.19" transform="translate(165.428 38.152)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_54" data-name="Line 54" x1="18.056" y2="10.45" transform="translate(147.372 33.836)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_55" data-name="Line 55" x1="17.884" y2="10.423" transform="translate(129.452 65.11)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_56" data-name="Line 56" x1="17.931" y1="10.238" transform="translate(111.52 65.296)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_57" data-name="Line 57" x1="14.217" y1="8.118" transform="translate(111.513 69.571)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_58" data-name="Line 58" x1="18.13" y2="10.267" transform="translate(93.39 65.296)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_59" data-name="Line 59" x1="0.034" y2="20.91" transform="translate(93.355 75.563)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_60" data-name="Line 60" x1="0.028" y2="16.526" transform="translate(97.123 77.759)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_61" data-name="Line 61" x2="18.151" y2="10.321" transform="translate(93.355 96.473)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_62" data-name="Line 62" y1="10.343" x2="17.896" transform="translate(111.507 96.451)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_63" data-name="Line 63" y1="8.204" x2="14.201" transform="translate(111.492 94.3)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_64" data-name="Line 64" y1="20.917" x2="0.049" transform="translate(129.402 75.533)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_65" data-name="Line 65" x1="11.951" y2="7.085" transform="translate(81.404 96.473)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_66" data-name="Line 66" x1="12.176" y1="6.943" transform="translate(57.195 96.626)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_67" data-name="Line 67" x1="17.938" y2="10.442" transform="translate(39.257 96.626)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_68" data-name="Line 68" x1="11.791" y1="6.59" transform="translate(27.466 100.478)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_69" data-name="Line 69" y1="10.394" x2="18.08" transform="translate(183.458 33.775)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_70" data-name="Line 70" x2="11.951" y2="6.947" transform="translate(201.538 33.775)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_71" data-name="Line 71" y1="14.196" x2="0.025" transform="translate(199.672 20.653)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
                <line id="Line_72" data-name="Line 72" y1="14.2" x2="0.025" transform="translate(203.405 20.659)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
            </g>
        </g>
        <g id="Group_20" data-name="Group 20">
            <text id="_Means_presented_in_table_are_Least_Square_LS_means" data-name="*Means presented in table are Least Square (LS) means" transform="translate(336 5473.997)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">'
                <tspan x="0" y="16">*Means presented in table are Least Square (LS) means</tspan>
            </text>
            <g id="Group_16" data-name="Group 16">
                <text id="Table_3._Acne_of_the_Face_Efficacy_Results_at_Week_12_Intent-to-Treat_Multiple_Imputation_" data-name="Table 3. Acne of the Face Efficacy Results at Week 12 (Intent-to-Treat; Multiple Imputation)" transform="translate(336 5172)" font-size="16" class="sofiapro-bold" font-weight="700">
                    <tspan x="0" y="16">Table 3. Acne of the Face Efficacy Results at Week 12 (Intent-to-Treat; Multiple Imputation)</tspan>
                </text>
                <g id="Group_9" data-name="Group 9" transform="translate(337.625 5202)">
                    <rect id="Rectangle_3" data-name="Rectangle 3" width="1025" height="266.233" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                    <line id="Line_73" data-name="Line 73" x2="1025" transform="translate(0 203.353)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                    <line id="Line_74" data-name="Line 74" x2="1025" transform="translate(0 139.473)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                    <line id="Line_75" data-name="Line 75" x2="1025" transform="translate(0 73.635)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                    <line id="Line_76" data-name="Line 76" x2="698" transform="translate(325.875 27.151)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                    <line id="Line_77" data-name="Line 77" y2="239.257" transform="translate(860.813 26.976)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                    <line id="Line_78" data-name="Line 78" y2="266.233" transform="translate(667.5)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                    <line id="Line_79" data-name="Line 79" y2="239.257" transform="translate(482.188 26.976)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                    <line id="Line_80" data-name="Line 80" y2="325.233" transform="translate(325.875)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                </g>
                <text id="IGA_Success_At_least_a_2-grade_improvement_and_Clear_0_or_Almost_Clear_1_" data-name="IGA Success At least a 2-grade improvement and “Clear” (0) or “Almost Clear” (1)" transform="translate(351.625 5278.919)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
                    <tspan fill="#000">
                        <tspan x="79.743" y="16">IGA Success</tspan>
                    </tspan>
                    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                        <tspan x="14.463" y="35">At least a 2-grade improvement and </tspan>
                        <tspan x="30.367" y="54">“Clear” (0) or “Almost Clear” (1)</tspan>
                    </tspan>
                </text>
                <text id="Inflammatory_Lesions_Mean_Absolute_Percent_Change_from_Baseline" data-name="Inflammatory Lesions Mean* Absolute (Percent)  Change from Baseline" transform="translate(351.625 5344.919)" font-size="16" class="sofiapro-bold" font-weight="700">
                    <tspan x="52.839" y="16">Inflammatory Lesions</tspan>
                    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                        <tspan x="43.791" y="35">Mean* Absolute (Percent) </tspan>
                        <tspan x="52.999" y="54">Change from Baseline</tspan>
                    </tspan>
                </text>
                <text id="Non-inflammatory_Lesions_Mean_Absolute_Percent_Change_from_Baseline" data-name="Non-inflammatory Lesions Mean* Absolute (Percent)  Change from Baseline" transform="translate(370.625 5407.919)" font-size="16" class="sofiapro-bold" font-weight="700">
                    <tspan x="20.175" y="16">Non-inflammatory Lesions</tspan>
                    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                        <tspan x="24.791" y="35">Mean* Absolute (Percent) </tspan>
                        <tspan x="33.999" y="54">Change from Baseline</tspan>
                    </tspan>
                </text>
                <text id="Study_1" data-name="Study 1" transform="translate(814.983 5222.337)" font-size="16" class="sofiapro-bold" font-weight="700">
                    <tspan x="-20.2" y="0">Study 1</tspan>
                </text>
                <text id="Study_2" data-name="Study 2" transform="translate(1190.577 5222.337)" font-size="16" class="sofiapro-bold" font-weight="700">
                    <tspan x="-20.992" y="0">Study 2</tspan>
                </text>
                <text id="AKLIEF_Cream_N_612_" data-name="AKLIEF Cream (N= 612)" transform="translate(679 5231.47)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                    <tspan x="8.35" y="16">AKLIEF Cream </tspan>
                    <tspan x="24.414" y="35">(N= 612)</tspan>
                </text>
                <text id="Vehicle_Cream_N_596_" data-name="Vehicle Cream (N= 596)" transform="translate(851 5231.47)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                    <tspan x="6.886" y="16">Vehicle Cream</tspan>
                    <tspan x="22.838" y="35">(N= 596)</tspan>
                </text>
                <text id="AKLIEF_Cream_N_602_" data-name="AKLIEF Cream (N= 602)" transform="translate(1035.245 5231.47)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                    <tspan x="8.35" y="16">AKLIEF Cream </tspan>
                    <tspan x="23.046" y="35">(N= 602)</tspan>
                </text>
                <text id="Vehicle_Cream_N_610_" data-name="Vehicle Cream (N=610)" transform="translate(1213 5231.47)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                    <tspan x="6.886" y="16">Vehicle Cream</tspan>
                    <tspan x="25.606" y="35">(N=610)</tspan>
                </text>
              <text id="_29.4_-19.0_-54.4_-25.0_-49.7_" data-name="29.4%-19.0 (-54.4%)-25.0 (-49.7%)" transform="translate(679 5300)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="31.422" y="16">29.4%</tspan>
                <tspan x="10.558" y="75">-19.0 (-54.4%)</tspan>
                <tspan x="10.054" y="134">-25.0 (-49.7%)</tspan>
            </text>
            <text id="_19.5_-15.4_-44.8_-17.9_-35.7_" data-name="19.5% -15.4 (-44.8%) -17.9 (-35.7%)" transform="translate(851 5300)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="32.398" y="16">19.5%</tspan>
                <tspan x="10.278" y="75">-15.4 (-44.8%)</tspan>
                <tspan x="11.958" y="134">-17.9 (-35.7%)</tspan>
            </text>
            <text id="_42.3_-24.2_-66.2_-30.1_-57.7_" data-name=" 42.3% -24.2 (-66.2%) -30.1 (-57.7%)" transform="translate(1035.245 5300)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="30.102" y="16" xml:space="preserve"> 42.3%</tspan>
                <tspan x="10.038" y="75">-24.2 (-66.2%)</tspan>
                <tspan x="12.19" y="134">-30.1 (-57.7%)</tspan>
            </text>
            <text id="_25.7_-18.7_-51.2_-21.6_-43.9_" data-name=" 25.7% -18.7 (-51.2%) -21.6 (-43.9%)" transform="translate(1216 5300)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="30.214" y="16" xml:space="preserve"> 25.7%</tspan>
                <tspan x="12.534" y="75">-18.7 (-51.2%)</tspan>
                <tspan x="10.918" y="134">-21.6 (-43.9%)</tspan>
            </text>
        </g>
    </g>
    <g id="Group_19" data-name="Group 19">
        <text id="_Means_presented_in_table_are_Least_Square_LS_means-2" data-name="*Means presented in table are Least Square (LS) means" transform="translate(336 5816.997)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
            <tspan x="0" y="16">*Means presented in table are Least Square (LS) means</tspan>
        </text>
        <g id="Group_18" data-name="Group 18" transform="translate(0 342)">
              <g id="Group_9-2" data-name="Group 9" transform="translate(337.625 5202)">
                <rect id="Rectangle_3-2" data-name="Rectangle 3" width="1025" height="266.233" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_73-2" data-name="Line 73" x2="1025" transform="translate(0 203.353)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_74-2" data-name="Line 74" x2="1025" transform="translate(0 139.473)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_75-2" data-name="Line 75" x2="1025" transform="translate(0 73.635)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_76-2" data-name="Line 76" x2="698" transform="translate(325.875 27.151)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_77-2" data-name="Line 77" y2="239.257" transform="translate(860.813 26.976)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_78-2" data-name="Line 78" y2="266.233" transform="translate(667.5)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_79-2" data-name="Line 79" y2="239.257" transform="translate(482.188 26.976)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
                <line id="Line_80-2" data-name="Line 80" y2="266.233" transform="translate(325.875)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
            </g>
            <text id="PGA_Success_At_least_a_2-grade_improvement_and_Clear_0_or_Almost_Clear_1_" data-name="PGA Success At least a 2-grade improvement and “Clear” (0) or “Almost Clear” (1)" transform="translate(351.625 5278.919)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
                <tspan fill="#000">
                    <tspan x="77.959" y="16">PGA Success</tspan>
                </tspan>
                <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                    <tspan x="14.463" y="35">At least a 2-grade improvement and </tspan>
                    <tspan x="30.367" y="54">“Clear” (0) or “Almost Clear” (1)</tspan>
                </tspan>
            </text>
            <text id="Inflammatory_Lesions_Mean_Absolute_Percent_Change_from_Baseline-2" data-name="Inflammatory Lesions Mean* Absolute (Percent)  Change from Baseline" transform="translate(351.625 5344.919)" font-size="16" class="sofiapro-bold" font-weight="700">
                <tspan x="52.839" y="16">Inflammatory Lesions</tspan>
                <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                    <tspan x="43.791" y="35">Mean* Absolute (Percent) </tspan>
                    <tspan x="52.999" y="54">Change from Baseline</tspan>
                </tspan>
            </text>
            <text id="Non-inflammatory_Lesions_Mean_Absolute_Percent_Change_from_Baseline-2" data-name="Non-inflammatory Lesions Mean* Absolute (Percent)  Change from Baseline" transform="translate(370.625 5407.919)" font-size="16" class="sofiapro-bold" font-weight="700">
                <tspan x="20.175" y="16">Non-inflammatory Lesions</tspan>
                <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                    <tspan x="24.791" y="35">Mean* Absolute (Percent) </tspan>
                    <tspan x="33.999" y="54">Change from Baseline</tspan>
                </tspan>
            </text>
            <text id="Study_1-2" data-name="Study 1" transform="translate(814.983 5222.337)" font-size="16" class="sofiapro-bold" font-weight="700">
                <tspan x="-20.2" y="0">Study 1</tspan>
            </text>
            <text id="Study_2-2" data-name="Study 2" transform="translate(1190.577 5222.337)" font-size="16" class="sofiapro-bold" font-weight="700">
                <tspan x="-20.992" y="0">Study 2</tspan>
            </text>
            <text id="AKLIEF_Cream_N_600_" data-name="AKLIEF Cream (N= 600)" transform="translate(679 5231.47)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="8.35" y="16">AKLIEF Cream </tspan>
                <tspan x="22.694" y="35">(N= 600)</tspan>
            </text>
            <text id="Vehicle_Cream_N_585_" data-name="Vehicle Cream (N= 585)" transform="translate(851 5231.47)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="6.886" y="16">Vehicle Cream</tspan>
                <tspan x="22.782" y="35">(N= 585)</tspan>
            </text>
            <text id="AKLIEF_Cream_N_598_" data-name="AKLIEF Cream (N= 598)" transform="translate(1035.245 5231.47)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="8.35" y="16">AKLIEF Cream </tspan>
                <tspan x="22.87" y="35">(N= 598)</tspan>
            </text>
            <text id="Vehicle_Cream_N_609_" data-name="Vehicle Cream(N=609)" transform="translate(1213 5231.47)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="6.886" y="16">Vehicle Cream</tspan>
                <tspan x="24.238" y="35">(N=609)</tspan>
            </text>
            <text id="_35.7_-21.4_-57.4_-21.9_-49.1_" data-name="35.7% -21.4 (-57.4%) -21.9 (-49.1%)" transform="translate(679 5300)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="31.574" y="16">35.7%</tspan>
                <tspan x="11.742" y="75">-21.4 (-57.4%)</tspan>
                <tspan x="12.414" y="134">-21.9 (-49.1%)</tspan>
            </text>
            <text id="_25.0_-18.8_-50.0_-17.8_-40.3_" data-name="25.0% -18.8 (-50.0%) -17.8 (-40.3%)" transform="translate(851 5300)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="31.31" y="16">25.0%</tspan>
                <tspan x="10.398" y="75">-18.8 (-50.0%)</tspan>
                <tspan x="11.574" y="134">-17.8 (-40.3%)</tspan>
            </text>
            <text id="_42.6_-25.5_-65.4_-25.9_-55.2_" data-name="42.6% -25.5 (-65.4%) -25.9 (-55.2%)" transform="translate(1035.245 5300)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="31.446" y="16">42.6%</tspan>
                <tspan x="9.294" y="75">-25.5 (-65.4%)</tspan>
                <tspan x="9.646" y="134">-25.9 (-55.2%)</tspan>
            </text>
            <text id="_29.9_-19.8_-51.1_-20.8_-45.1_" data-name="29.9%-19.8 (-51.1%)-20.8 (-45.1%)" transform="translate(1216 5300)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
                <tspan x="31.366" y="16">29.9%</tspan>
                <tspan x="13.51" y="75">-19.8 (-51.1%)</tspan>
                <tspan x="10.966" y="134">-20.8 (-45.1%)</tspan>
            </text>
        </g>
        <text id="Table_4._Acne_of_the_Trunk_Efficacy_Results_at_Week_12_Intent-to-Treat_on_the_Trunk_Multiple_Imputation_" data-name="Table 4. Acne of the Trunk Efficacy Results at Week 12 (Intent-to-Treat on the Trunk; Multiple Imputation)" transform="translate(337.625 5514.487)" fill="#1a1818" font-size="16" class="sofiapro-bold" font-weight="700">
            <tspan x="0" y="16">Table 4. Acne of the Trunk Efficacy Results at Week 12 (Intent-to-Treat on the Trunk; Multiple Imputation)</tspan>
        </text>
    </g>
    <line id="Line_89" data-name="Line 89" x2="1000" transform="translate(336 592.026)" fill="none" stroke="#1a1818" stroke-width="1"/>
    <line id="Line_90" data-name="Line 90" x2="1000" transform="translate(336 958.026)" fill="none" stroke="#1a1818" stroke-width="1"/>
    <g id="Group_4" data-name="Group 4" transform="translate(338 2230.643)">
        <path id="Path_6" data-name="Path 6" d="M0-30.049H1000v350.2H0Z" transform="translate(0 0)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_6" data-name="Line 6" x2="1000" transform="translate(0 271.823)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_7" data-name="Line 7" x2="1000" transform="translate(0 247.491)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <path id="Path_8" data-name="Path 8" d="M3.281,8.012H1000.563" transform="translate(-3.281 214.752)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_9" data-name="Line 9" x2="1000" transform="translate(0 195.012)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_10" data-name="Line 10" x2="1000" transform="translate(0 67.273)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <path id="Path_10" data-name="Path 10" d="M0,0H1000" transform="translate(0 163.349)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_12" data-name="Line 12" x2="1000" transform="translate(0 118.61)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_13" data-name="Line 13" x2="1000" transform="translate(0 92.87)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_14" data-name="Line 14" x2="1000" transform="translate(0 41.092)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <path id="Path_7" data-name="Path 7" d="M2.816-17.01h1000" transform="translate(0 32.331)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_16" data-name="Line 16" y2="125" transform="translate(880.225 194.857)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_17" data-name="Line 17" y2="148.027" transform="translate(880.225 15.322)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_18" data-name="Line 18" y2="125" transform="translate(710.143 194.857)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_19" data-name="Line 19" y2="148.027" transform="translate(710.143 15.322)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_20" data-name="Line 20" y2="350" transform="translate(560.714 -30.143)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <path id="Path_9" data-name="Path 9" d="M-3.208-38.222v125" transform="translate(405.286 233.079)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_22" data-name="Line 22" y2="148.027" transform="translate(405.286 15.322)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_23" data-name="Line 23" x1="0.357" y2="125" transform="translate(255.5 194.857)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_24" data-name="Line 24" y2="148.027" transform="translate(255.857 15.322)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
        <line id="Line_25" data-name="Line 25" x1="0.275" y2="350" transform="translate(120.5 -30.143)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
    </g>
</g>
    <text id="Marketed_by:_GALDERMA_LABORATORIES_L.P._Fort_Worth_Texas_76177_USA_All_trademarks_are_the_property_of_their_respective_owners._Made_in_Canada_This_Patient_Information_has_been_approved_by_the_U.S._Food_and_Drug_Administration._Issued:_10_2019_P54485-" data-name="Marketed by: GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA All trademarks are the property of their respective owners. Made in Canada This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 10/2019P54485-" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300" transform="translate(0 6221.643)">
        <tspan x="0" y="12">Marketed by:</tspan>
        <tspan x="0" y="31">GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA</tspan>
        <tspan x="0" y="50">All trademarks are the property of their respective owners.</tspan>
        <tspan x="0" y="69">Made in Canada</tspan>
    </text>
<text id="Important:_AKLIEF_Cream_is_for_use_on_the_skin_only._Do_not_use_AKLIEF_Cream_in_your_mouth_eyes_or_vagina._What_is_AKLIEF_Cream_AKLIEF_Cream_is_a_prescription_medicine_used_on_the_skin_topical_to_treat_acne_vulgaris_in_people_9_years_of_age_and_olde" data-name="Important: AKLIEF Cream is for use on the skin only.  Do not use AKLIEF Cream in your mouth, eyes, or vagina.What is AKLIEF Cream?AKLIEF Cream is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 9 years of age and olde" transform="translate(0.25 6393)" font-size="16" class="sofiapro-bold" font-weight="700">
    <tspan x="0" y="16">Important:</tspan>
    <tspan y="16" xml:space="preserve" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"> AKLIEF Cream is for use on the skin only.  Do not use AKLIEF Cream in your mouth, eyes, or vagina.</tspan>
    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="35"></tspan>
    </tspan>
    <tspan x="0" y="54">What is AKLIEF Cream?</tspan>
    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="73">AKLIEF Cream is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 9 years of age and older.</tspan>
        <tspan x="0" y="92">It is not known if AKLIEF Cream is safe and effective in children younger than 9 years old.</tspan>
        <tspan x="0" y="111"></tspan>
    </tspan>
    <tspan x="0" y="130">Before using AKLIEF Cream, tell your healthcare provider about all of your medical conditions, including if you:</tspan>
    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="149" xml:space="preserve">•   have skin problems, including eczema, cuts or sunburn</tspan>
        <tspan x="0" y="168" xml:space="preserve">•   are pregnant or planning to become pregnant. It is not known if AKLIEF Cream will harm your unborn baby.</tspan>
        <tspan x="0" y="187" xml:space="preserve">•   are breastfeeding or plan to breastfeed. It is not known if AKLIEF Cream passes into your breast milk. Breastfeeding women should use </tspan>
        <tspan x="0" y="206" xml:space="preserve">     AKLIEF Cream on the smallest area of skin and for the shortest time needed while breastfeeding. Do not apply AKLIEF Cream to the nipple      </tspan>
        <tspan x="0" y="225" xml:space="preserve">     and areola to avoid contact with your baby.</tspan>
    </tspan>
    <tspan x="0" y="244">Tell your healthcare provider about all the medicines you take,</tspan>
    <tspan y="244" xml:space="preserve" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"> including prescription and over-the-counter medicines, vitamins and </tspan>
    <tspan x="0" y="263" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">herbal supplements.</tspan>
    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="282">Especially tell your healthcare provider if you use any other medicine for acne.</tspan>
        <tspan x="0" y="301"></tspan>
    </tspan>
    <tspan x="0" y="320">How should I use AKLIEF Cream?</tspan>
    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="339" xml:space="preserve">•   Use AKLIEF Cream exactly as your healthcare provider tells you to use it. Apply a thin layer of AKLIEF Cream over the affected areas 1 time </tspan>
        <tspan x="0" y="358" xml:space="preserve">     each day, in the evening.</tspan>
    </tspan>
    <tspan x="0" y="377">Applying AKLIEF Cream:</tspan>
    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="396" xml:space="preserve">•   Wash the area where the cream will be applied and pat dry.</tspan>
        <tspan x="0" y="415" xml:space="preserve">•   If you receive a sample tube of AKLIEF Cream, follow your healthcare provider’s instructions about how much to apply.</tspan>
        <tspan x="0" y="434" xml:space="preserve">•   AKLIEF Cream comes in a pump.</tspan>
        <tspan x="0" y="453" xml:space="preserve">    -   Press down on (depress) the pump 1 time to dispense a small amount of AKLIEF Cream and spread a thin layer over your face </tspan>
        <tspan x="0" y="472" xml:space="preserve">         (forehead, cheeks, nose, and chin). Avoid contact with your eyes, lips, mouth, and the corners of your nose.</tspan>
        <tspan x="0" y="491" xml:space="preserve">    -   Press down on the pump 2 times to dispense enough AKLIEF Cream to apply a thin layer to cover your upper trunk (the area of your </tspan>
        <tspan x="0" y="510" xml:space="preserve">         upper back that you can reach, shoulders, and chest). One more pump may be used to apply a thin layer of AKLIEF Cream to your </tspan>
        <tspan x="0" y="529" xml:space="preserve">         middle and lower back, if acne is present.</tspan>
        <tspan x="0" y="548" xml:space="preserve">•   When you begin treatment with AKLIEF Cream, you should begin applying a moisturizer on your skin as often as needed. </tspan>
        <tspan y="548" class="sofiapro-bold" font-weight="700">See “Local skin </tspan>
    </tspan>
    <tspan x="0" y="567" xml:space="preserve">     irritation”</tspan>
    <tspan y="567" xml:space="preserve" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"> below.</tspan>
    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="586"></tspan>
    </tspan>
    <tspan x="0" y="605">What should I avoid while using AKLIEF Cream?</tspan>
    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="624" xml:space="preserve">•   Minimize exposure to sunlight. You should avoid using sunlamps, tanning beds, and ultraviolet light during treatment with AKLIEF Cream. </tspan>
        <tspan x="0" y="643" xml:space="preserve">     If you have to be in sunlight or are sensitive to sunlight, use a sunscreen with an SPF (sun protection factor) of 15 or more, and wear </tspan>
        <tspan x="0" y="662" xml:space="preserve">     protective clothing and a wide-brimmed hat to cover the treated areas.</tspan>
        <tspan x="0" y="681" xml:space="preserve">•   Avoid using AKLIEF Cream on skin areas with cuts, abrasions, eczema, or on sunburned skin.</tspan>
        <tspan x="0" y="700" xml:space="preserve">•   Avoid using skin products that may dry or irritate your skin, such as: </tspan>
        <tspan x="0" y="719" xml:space="preserve">    -   medicated or abrasive soaps and cleansers</tspan>
        <tspan x="0" y="738" xml:space="preserve">    -   soaps, cleansers, and cosmetics that have strong skin drying effects</tspan>
        <tspan x="0" y="757" xml:space="preserve">    -   products that contain high amounts of alcohol</tspan>
        <tspan x="0" y="776">• Avoid the use of “waxing” as a hair removal method on skin treated with AKLIEF Cream.</tspan>
        <tspan x="0" y="795"></tspan>
    </tspan>
    <tspan x="0" y="814">What are the possible side effects of AKLIEF Cream?</tspan>
    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="833">AKLIEF Cream may cause serious side effects including:</tspan>
        <tspan x="0" y="852" xml:space="preserve">•   </tspan>
        <tspan y="852" class="sofiapro-bold" font-weight="700">Local skin irritation.</tspan>
        <tspan y="852" xml:space="preserve"> Local skin reactions are common with AKLIEF Cream, are most likely to happen during the first 4 weeks of treatment </tspan>
        <tspan x="0" y="871" xml:space="preserve">     and may decrease with continued use of AKLIEF Cream. Signs and symptoms of local skin reactions include:</tspan>
        <tspan x="0" y="890" xml:space="preserve">    -   redness     - dryness</tspan>
        <tspan x="0" y="909" xml:space="preserve">    -   scaling      - stinging or burning</tspan>
        <tspan x="0" y="928" xml:space="preserve">     To help reduce your risk of developing these local skin reactions, when you begin treatment with AKLIEF Cream, you should begin applying </tspan>
        <tspan x="0" y="947" xml:space="preserve">     a moisturizer on your skin as often as needed.</tspan>
        <tspan x="0" y="966" xml:space="preserve">     Tell your healthcare provider if you develop symptoms of a local skin reaction. Your doctor may tell you to use AKLIEF Cream less often, or </tspan>
        <tspan x="0" y="985" xml:space="preserve">     temporarily, or permanently stop your treatment with AKLIEF Cream.</tspan>
        <tspan x="0" y="1004" xml:space="preserve">     The most common side effects of AKLIEF Cream include: itching and sunburn. </tspan>
        <tspan y="1004" class="sofiapro-bold" font-weight="700">See “What should I avoid while using AKLIEF Cream”.</tspan>
        <tspan x="0" y="1023" xml:space="preserve">     These are not all the possible side effects of AKLIEF Cream. For more information, ask your healthcare provider or pharmacist.</tspan>
        <tspan x="0" y="1042" xml:space="preserve">     Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.</tspan>
        <tspan x="0" y="1061" xml:space="preserve">     You may also report side effects to GALDERMA LABORATORIES, L.P. at 1-866-735-4137.</tspan><tspan x="0" y="1080"></tspan>
    </tspan>
    <tspan x="0" y="1099">How should I store AKLIEF Cream?</tspan>
    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="1118">• Store AKLIEF Cream at room temperature, 68° to 77° F (20° to 25°C).</tspan>
        <tspan x="0" y="1137">• Keep AKLIEF Cream away from heat.</tspan>
        <tspan x="0" y="1156">• If you receive a sample tube of AKLIEF Cream from your healthcare provider, keep the tube tightly closed.</tspan>
    </tspan>
    <tspan x="0" y="1175">Keep AKLIEF Cream and all medicines out of the reach of children.</tspan>
    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="1194"></tspan>
    </tspan>
    <tspan x="0" y="1213">General information about the safe and effective use of AKLIEF Cream.</tspan>
    <tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="1232">Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use AKLIEF Cream for a </tspan>
        <tspan x="0" y="1251">condition for which it was not prescribed. Do not give AKLIEF Cream to other people, even if they have the same symptoms you have. It may </tspan>
        <tspan x="0" y="1270">harm them. You can ask your pharmacist or healthcare provider for information about AKLIEF Cream that is written for health professionals.</tspan>
        <tspan x="0" y="1289"></tspan>
    </tspan>
    <tspan x="0" y="1308">What are the ingredients in AKLIEF Cream?</tspan>
    <tspan x="0" y="1327">Active ingredient: </tspan>
    <tspan y="1327" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">trifarotene</tspan>
    <tspan x="0" y="1346">Inactive ingredients:</tspan>
    <tspan y="1346" xml:space="preserve" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"> allantoin, copolymer of acrylamide and sodium acryloyldimethyltaurate, dispersion 40% in isohexadecane, </tspan>
    <tspan x="0" y="1365" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">cyclomethicone, 5% ethanol, medium-chain triglycerides, phenoxyethanol, propylene glycol, purified water.</tspan>
</text>
<line id="Line_91" data-name="Line 91" x2="1025" transform="translate(0 6327.026)" fill="none" stroke="#1a1818" stroke-width="1"/>
<text id="Patient_Information_AKLIEF_trifarotene_cream" data-name="Patient Information AKLIEF® (trifarotene) cream" transform="translate(105.25 6344)" font-size="16" class="sofiapro-bold" font-weight="700">
    <tspan x="328.416" y="16">Patient Information </tspan>
    <tspan x="303.088" y="35">AKLIEF® (trifarotene) cream</tspan>
</text>
</g>
</svg>

<!-- END OF COPYING FROM DESKTOP --> 

<!-- testing something here --> 
<svg id="mobile" class="mobile" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" width="813" height="13216" viewBox="0 0 813 13216">
 
  <text id="These_highlights_do_not_include_all_the_information_needed_to_use_AKLIEF_Cream_safely_and_effectively._See_full_prescribing_information_for_AKLIEF_Cream._AKLIEF_trifarotene_cream_for_topical_use_Initial_U.S._Approval:_2019_-_INDICATIONS_AND_U" data-name="These highlights do not include all the information needed to use AKLIEF® Cream safely and effectively. See full prescribing information for AKLIEF Cream.
AKLIEF (trifarotene) cream, for topical use
Initial U.S. Approval: 2019

————-—————INDICATIONS AND U" transform="translate(46 142)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16">These highlights do not include all the information needed </tspan><tspan x="0" y="35">to use AKLIEF</tspan><tspan y="35" font-size="9.333" baseline-shift="5.33279994943018">®</tspan><tspan y="35" xml:space="preserve"> Cream safely and effectively. See full </tspan><tspan x="0" y="54">prescribing information for AKLIEF Cream.</tspan><tspan x="0" y="73">AKLIEF (trifarotene) cream, for topical use</tspan><tspan x="0" y="92">Initial U.S. Approval: 2019</tspan><tspan x="0" y="111"></tspan><tspan x="0" y="130">————-—————INDICATIONS AND USAGE————————-</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="149">AKLIEF Cream is a retinoid indicated for the topical treatment </tspan><tspan x="0" y="168">of acne vulgaris in patients 9 years of age and older. (1)</tspan></tspan><tspan x="0" y="187"></tspan><tspan x="0" y="206">—————-——DOSAGE AND ADMINISTRATION———————</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="225" xml:space="preserve">•   For topical use only. Not for oral, ophthalmic or </tspan><tspan x="0" y="244" xml:space="preserve">     intravaginal use.</tspan><tspan x="0" y="263" xml:space="preserve">•   Apply a thin layer of AKLIEF Cream to the affected areas of        </tspan><tspan x="0" y="282" xml:space="preserve">     the face and/or trunk once a day, in the evening, on clean </tspan><tspan x="0" y="301" xml:space="preserve">     and dry skin. Avoid contact with the eyes, lips, paranasal </tspan><tspan x="0" y="320" xml:space="preserve">     creases, and mucous membranes. (2)</tspan></tspan><tspan x="0" y="339"></tspan><tspan x="0" y="358">———————DOSAGE FORMS AND STRENGTHS———————</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="377">Cream: 0.005% trifarotene. (3)</tspan></tspan><tspan x="0" y="396"></tspan><tspan x="0" y="415">——————————CONTRAINDICATIONS——————————</tspan><tspan font-family="SofiaProCondensed-Regular, Sofia Pro Condensed" font-weight="400"><tspan x="0" y="434">None (4)</tspan></tspan></text>
  <text id="HIGHLIGHTS_OF_PRESCRIBING_INFORMATION" data-name="HIGHLIGHTS OF PRESCRIBING INFORMATION" transform="translate(28 109)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="61.648" y="16">HIGHLIGHTS OF PRESCRIBING INFORMATION</tspan></text>
  <text id="_1_INDICATIONS_AND_USAGE_2_DOSAGE_AND_ADMINISTRATION_3_DOSAGE_FORMS_AND_STRENGTHS_4_CONTRAINDICATIONS_5_WARNINGS_AND_PRECAUTIONS_5.1_Skin_Irritation_5.2_Ultraviolet_Light_and_Environmental_Exposure_6_ADVERSE_REACTIONS_6.1_Clinical_Trials_Experie" data-name="1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
    5.1 Skin Irritation
    5.2 Ultraviolet Light and Environmental Exposure
6 ADVERSE REACTIONS
    6.1 Clinical Trials Experie" transform="translate(45 1115)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16">1 INDICATIONS AND USAGE</tspan><tspan x="0" y="35">2 DOSAGE AND ADMINISTRATION</tspan><tspan x="0" y="54">3 DOSAGE FORMS AND STRENGTHS</tspan><tspan x="0" y="73">4 CONTRAINDICATIONS</tspan><tspan x="0" y="92">5 WARNINGS AND PRECAUTIONS</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="111" xml:space="preserve">    5.1 Skin Irritation</tspan><tspan x="0" y="130" xml:space="preserve">    5.2 Ultraviolet Light and Environmental Exposure</tspan></tspan><tspan x="0" y="149">6 ADVERSE REACTIONS</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="168" xml:space="preserve">    6.1 Clinical Trials Experience</tspan></tspan><tspan x="0" y="187">7 DRUG INTERACTIONS</tspan><tspan x="0" y="206">8 USE IN SPECIFIC POPULATIONS</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="225" xml:space="preserve">    8.1 Pregnancy</tspan><tspan x="0" y="244" xml:space="preserve">    8.2 Lactation</tspan><tspan x="0" y="263" xml:space="preserve">    8.4 Pediatric Use</tspan><tspan x="0" y="282" xml:space="preserve">    8.5 Geriatric Use</tspan></tspan></text>
  <text id="FULL_PRESCRIBING_INFORMATION:_CONTENTS_" data-name="FULL PRESCRIBING INFORMATION: CONTENTS*" transform="translate(0 1077)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="84.016" y="16">FULL PRESCRIBING INFORMATION: CONTENTS*</tspan></text>
  <line id="Line_89" data-name="Line 89" x2="342.5" transform="translate(45 1054.026)" fill="none" stroke="#1a1818" stroke-width="1"/>
  <line id="Line_90" data-name="Line 90" x2="340.5" transform="translate(45 1663.026)" fill="none" stroke="#1a1818" stroke-width="1"/>
  <text id="Additional_adverse_reactions_that_were_reported_in_more_than_one_subject_treated_with_AKLIEF_Cream_and_at_a_frequency_1_included_application_site_pain_application_site_dryness_application_site_discoloration_application_site_rash_application_site_sw" data-name="Additional adverse reactions that were reported in more than one subject treated with AKLIEF Cream (and at a frequency &lt;1%) included application site pain, application site dryness, application site discoloration, application site rash, application site sw" transform="translate(45 3182)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="16">Additional adverse reactions that were reported in more than </tspan><tspan x="0" y="35">one subject treated with AKLIEF Cream (and at a frequency </tspan><tspan x="0" y="54">&lt;1%) included application site pain, application site dryness, </tspan><tspan x="0" y="73">application site discoloration, application site rash, application </tspan><tspan x="0" y="92">site swelling, application site erosion, acne, dermatitis allergic, </tspan><tspan x="0" y="111">and erythema.</tspan><tspan x="0" y="130"></tspan><tspan x="0" y="149">In the one-year, open-label safety trial that included 453 </tspan><tspan x="0" y="168">subjects 9 years and older, with acne vulgaris of the face and </tspan><tspan x="0" y="187">trunk, the pattern of adverse reactions for AKLIEF Cream was </tspan><tspan x="0" y="206">similar to that experienced in the 12-week controlled trials. A </tspan><tspan x="0" y="225">total of 12.6% of subjects had at least one adverse reaction </tspan><tspan x="0" y="244">during the trial, and 2.9% of subjects had an adverse reaction </tspan><tspan x="0" y="263">leading to treatment discontinuation. The most common </tspan><tspan x="0" y="282">adverse reactions (≥ 1% of subjects) for the entire trial were </tspan><tspan x="0" y="301">application site pruritus (4.6%), application site irritation (4.2%), </tspan><tspan x="0" y="320">and sunburn (5.5%). The frequency of adverse reactions </tspan><tspan x="0" y="339">decreased over time.</tspan><tspan x="0" y="358"></tspan><tspan x="0" y="377">Skin irritation was evaluated by active assessment of </tspan><tspan x="0" y="396">erythema, scaling, dryness, and stinging/burning and </tspan><tspan x="0" y="415">collected separately. In the two 12-week Phase 3 clinical trials, </tspan><tspan x="0" y="434">these signs/symptoms were assessed at baseline and at least </tspan><tspan x="0" y="453">one post-baseline visit, in 1214 subjects (for face) and 1202 </tspan><tspan x="0" y="472">subjects (for trunk) treated with AKLIEF Cream. The percentage </tspan><tspan x="0" y="491">of subjects who were assessed to have these signs and </tspan><tspan x="0" y="510">symptoms at any post baseline visit and at a severity worse </tspan><tspan x="0" y="529">than baseline are summarized in Table 2.</tspan></text>
  <text id="Local_tolerability_on_the_face_in_subjects_treated_with_AKLIEF_Cream_worsened_for_any_of_the_signs_symptoms_compared_with_baseline_to_a_score_of_moderate_for_up_to_30_of_subjects_or_severe_for_up_to_6_of_subjects._On_the_trunk_the_corresponding_percent" data-name="Local tolerability on the face in subjects treated with AKLIEF Cream worsened for any of the signs/symptoms compared with baseline to a score of moderate for up to 30% of subjects, or severe for up to 6% of subjects. On the trunk, the corresponding percent" transform="translate(45 4139)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="16">Local tolerability on the face in subjects treated with AKLIEF </tspan><tspan x="0" y="35">Cream worsened for any of the signs/symptoms compared </tspan><tspan x="0" y="54">with baseline to a score of moderate for up to 30% of subjects, </tspan><tspan x="0" y="73">or severe for up to 6% of subjects. On the trunk, the </tspan><tspan x="0" y="92">corresponding percentages were up to 19% (moderate) and </tspan><tspan x="0" y="111">up to 5% (severe). The scores reached maximum severity at </tspan><tspan x="0" y="130">Week 1 for the face, and at Week 2 to 4 of treatment for the </tspan><tspan x="0" y="149">trunk, and decreased thereafter.</tspan><tspan x="0" y="168">In the open-label, 1-year Phase 3 trial, the local tolerability </tspan><tspan x="0" y="187">profile was comparable to that observed in the two pivotal </tspan><tspan x="0" y="206">Phase 3 trials.</tspan><tspan font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="225" xml:space="preserve">7   DRUG INTERACTIONS</tspan></tspan><tspan x="0" y="244">Topical application of AKLIEF Cream is not expected to affect </tspan><tspan x="0" y="263">the circulating concentrations of oral hormonal </tspan><tspan x="0" y="282">contraceptives containing ethinyl estradiol and </tspan><tspan x="0" y="301">levonorgestrel.</tspan><tspan font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="320" xml:space="preserve">8   USE IN SPECIFIC POPULATIONS</tspan><tspan x="0" y="339" xml:space="preserve">     8.1   Pregnancy</tspan></tspan><tspan x="0" y="358" xml:space="preserve">     </tspan><tspan y="358" text-decoration="underline">Risk Summary</tspan></text>
  <text id="Available_data_from_clinical_trials_with_AKLIEF_Cream_use_in_pregnant_women_have_not_identified_a_drug-associated_risk_of_major_birth_defects_miscarriage_or_adverse_maternal_or_fetal_outcomes._There_are_case_reports_of_major_birth_defects_similar_to_thos" data-name="Available data from clinical trials with AKLIEF Cream use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.  There are case reports of major birth defects similar to thos" transform="translate(61 4501)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="16">Available data from clinical trials with AKLIEF Cream use in </tspan><tspan x="0" y="35">pregnant women have not identified a drug-associated </tspan><tspan x="0" y="54">risk of major birth defects, miscarriage or adverse </tspan><tspan x="0" y="73" xml:space="preserve">maternal or fetal outcomes.  There are case reports of </tspan><tspan x="0" y="92">major birth defects similar to those seen in fetuses exposed </tspan><tspan x="0" y="111">to oral retinoids in pregnant women exposed to other </tspan><tspan x="0" y="130">topical retinoids, but these case reports do not establish a </tspan><tspan x="0" y="149">pattern or association with retinoid-related embryopathy.</tspan><tspan x="0" y="168">In animal reproduction studies, oral doses of trifarotene </tspan><tspan x="0" y="187">administered to pregnant rats and rabbits during </tspan><tspan x="0" y="206">organogenesis that resulted in systemic exposures more </tspan><tspan x="0" y="225">than 800 times the systemic exposure at the maximum </tspan><tspan x="0" y="244">recommended human dose (MRHD) of AKLIEF Cream </tspan><tspan x="0" y="263">resulted in adverse fetal effects, including fetal deaths and </tspan><tspan x="0" y="282">external, visceral, and skeletal malformations (see Data). </tspan><tspan x="0" y="301">The background risk of major birth defects and </tspan><tspan x="0" y="320">miscarriage for the indicated population is unknown. All </tspan><tspan x="0" y="339">pregnancies have a background risk of birth defect, loss, or </tspan><tspan x="0" y="358">other adverse outcomes. In the US general population, the </tspan><tspan x="0" y="377">estimated background risk of major birth defects and </tspan><tspan x="0" y="396">miscarriage in clinically recognized pregnancies is 2% to </tspan><tspan x="0" y="415">4% and 15% to 20%, respectively.</tspan><tspan text-decoration="underline"><tspan x="0" y="434">Data</tspan></tspan><tspan font-family="SofiaProCondensed-Lightitalic, Sofia Pro Condensed" font-style="italic"><tspan x="0" y="453">Animal Data</tspan></tspan><tspan x="0" y="472">Oral administration of trifarotene to pregnant rats during </tspan><tspan x="0" y="491">the period of organogenesis at doses that resulted in </tspan><tspan x="0" y="510">systemic exposures greater than 1600 times those in </tspan><tspan x="0" y="529">humans at the MRHD of AKLIEF Cream resulted in adverse </tspan><tspan x="0" y="548">fetal effects, including fetal deaths, reduced mean fetal </tspan><tspan x="0" y="567">weight, and external, visceral, and skeletal malformations.</tspan><tspan x="0" y="586">Oral administration of trifarotene to pregnant rabbits </tspan><tspan x="0" y="605">during the period of organogenesis at doses that resulted </tspan><tspan x="0" y="624">in systemic exposures at least 800 times those in humans </tspan><tspan x="0" y="643">at the MRHD of AKLIEF Cream resulted in adverse fetal </tspan><tspan x="0" y="662">effects, including defects of the tail, limbs, urogenital </tspan><tspan x="0" y="681">organs, and vertebral column.</tspan><tspan x="0" y="700">Trifarotene administered orally to female rats from </tspan><tspan x="0" y="719">gestation Day 6 to lactation Day 20, at doses that resulted </tspan><tspan x="0" y="738">in systemic exposures up to 594 times those in humans at </tspan><tspan x="0" y="757">the MRHD of AKLIEF Cream, had no effect on maternal </tspan><tspan x="0" y="776">function or behavior, including gestation, delivery, pup-</tspan><tspan x="0" y="795">rearing, lactation and nursing, or survival or development </tspan><tspan x="0" y="814">of pups. There were no effects of maternal treatment on </tspan><tspan x="0" y="833">behavior, learning, memory, or reproductive function of </tspan><tspan x="0" y="852">pups.</tspan><tspan font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="871" xml:space="preserve">8.2   Lactation</tspan></tspan><tspan text-decoration="underline"><tspan x="0" y="890">Risk Summary</tspan></tspan><tspan x="0" y="909">There are no data on the presence of trifarotene in human </tspan><tspan x="0" y="928">milk, the effects on the breastfed infant, or the effects on </tspan><tspan x="0" y="947">milk production. In animal studies, trifarotene was present </tspan><tspan x="0" y="966">in rat milk with oral administration of the drug. When a </tspan><tspan x="0" y="985">drug is present in animal milk, it is likely that the drug will </tspan><tspan x="0" y="1004">be present in human milk. It is possible that topical </tspan><tspan x="0" y="1023">administration of large amounts of trifarotene could result </tspan><tspan x="0" y="1042">in sufficient systemic absorption to produce detectable </tspan><tspan x="0" y="1061">quantities in human milk (see Clinical Considerations). The </tspan><tspan x="0" y="1080">developmental and health benefits of breastfeeding </tspan><tspan x="0" y="1099">should be considered along with the mother’s clinical need </tspan><tspan x="0" y="1118">for AKLIEF Cream and any potential adverse effects on the </tspan><tspan x="0" y="1137">breastfed infant from AKLIEF Cream or from the underlying </tspan><tspan x="0" y="1156">maternal condition.</tspan><tspan text-decoration="underline"><tspan x="0" y="1175">Clinical Considerations</tspan></tspan><tspan x="0" y="1194">To minimize potential exposure to the breastfed infant via </tspan><tspan x="0" y="1213">breastmilk, use AKLIEF Cream on the smallest area of skin </tspan><tspan x="0" y="1232">and for the shortest duration possible while breastfeeding. </tspan><tspan x="0" y="1251">Advise breastfeeding women not to apply AKLIEF Cream </tspan><tspan x="0" y="1270">directly to the nipple and areola to avoid direct infant </tspan><tspan x="0" y="1289">exposure.</tspan><tspan font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="1308" xml:space="preserve">8.4   Pediatric Use</tspan></tspan><tspan x="0" y="1327">Safety and effectiveness of AKLIEF Cream for the topical </tspan><tspan x="0" y="1346">treatment of acne vulgaris have been established in </tspan><tspan x="0" y="1365">pediatric patients age 9 years to 17 years based on </tspan><tspan x="0" y="1384">evidence from well-controlled clinical trials, long-term </tspan><tspan x="0" y="1403">safety trial, and a pharmacokinetic trial. A total of 897 </tspan><tspan x="0" y="1422">pediatric subjects aged 9 to 17 years received AKLIEF </tspan><tspan x="0" y="1441">Cream in the clinical trials [see Clinical Pharmacology </tspan><tspan x="0" y="1460">(12.3) and Clinical Studies (14)].</tspan><tspan x="0" y="1479">Safety and effectiveness of AKLIEF Cream have not been </tspan><tspan x="0" y="1498">established in pediatric subjects under the age of 9 years.</tspan><tspan font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="1517" xml:space="preserve">8.5   Geriatric use</tspan></tspan><tspan x="0" y="1536">Clinical trials of AKLIEF Cream did not include any subjects </tspan><tspan x="0" y="1555">aged 65 years and over to determine whether they </tspan><tspan x="0" y="1574">respond differently than younger subjects.</tspan></text>
  <text id="_11_DESCRIPTION_AKLIEF_Cream_for_topical_administration_contains_0.005_50_mcg_g_trifarotene._Trifarotene_is_a_terphenyl_acid_derivative_and_is_a_retinoid._The_chemical_name_of_trifarotene_is_3_-tert-Butyl-4_-_2-hydroxy-ethoxy_-4_-pyrrolidin-1-yl-_1_1_3" data-name="11  DESCRIPTION
AKLIEF Cream for topical administration contains 0.005% (50 mcg/g) trifarotene. Trifarotene is a terphenyl acid derivative and is a retinoid. The chemical name of trifarotene is 3”-tert-Butyl-4’-(2-hydroxy-ethoxy)-4”-pyrrolidin-1-yl-[1,1’,3" transform="translate(45 6081)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16" xml:space="preserve">11  DESCRIPTION</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="35">AKLIEF Cream for topical administration contains 0.005% (50 </tspan><tspan x="0" y="54">mcg/g) trifarotene. Trifarotene is a terphenyl acid derivative </tspan><tspan x="0" y="73">and is a retinoid. The chemical name of trifarotene is 3”-tert-</tspan><tspan x="0" y="92">Butyl-4’-(2-hydroxy-ethoxy)-4”-pyrrolidin-1-yl-[1,1’,3’1”] </tspan><tspan x="0" y="111">terphenyl-4-carboxylic acid. Trifarotene has the molecular </tspan><tspan x="0" y="130">formula of C29H33NO4, the molecular weight of 459.58, and </tspan><tspan x="0" y="149">the following structural formula:</tspan></tspan></text>
  <text id="Trifarotene_is_a_white_to_off-white_to_slightly_yellow_powder_with_the_melting_point_of_245_C._It_is_practically_insoluble_in_water_with_pKa1_of_5.69_and_pKa2_of_4.55._AKLIEF_trifarotene_Cream_0.005_contains_the_following_inactive_ingredients:_allantoin" data-name="Trifarotene is a white to off-white to slightly yellow powder with the melting point of 245°C. It is practically insoluble in water with pKa1 of 5.69 and pKa2 of 4.55. AKLIEF (trifarotene) Cream 0.005% contains the following inactive ingredients: allantoin" transform="translate(45 6398)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="16">Trifarotene is a white to off-white to slightly yellow powder </tspan><tspan x="0" y="35">with the melting point of 245°C. It is practically insoluble in </tspan><tspan x="0" y="54">water with pKa1 of 5.69 and pKa2 of 4.55. AKLIEF (trifarotene) </tspan><tspan x="0" y="73">Cream 0.005% contains the following inactive ingredients: </tspan><tspan x="0" y="92">allantoin, copolymer of acrylamide and sodium </tspan><tspan x="0" y="111">acryloyldimethyltaurate, dispersion 40% in isohexadecane, </tspan><tspan x="0" y="130">cyclomethicone, 5% ethanol, medium-chain triglycerides, </tspan><tspan x="0" y="149">phenoxyethanol, propylene glycol, purified water.</tspan><tspan font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="170" xml:space="preserve">12  CLINICAL PHARMACOLOGY</tspan></tspan></text>
  <text id="_13.1_Carcinogenesis_Mutagenesis_Impairment_of_Fertility_Trifarotene_was_not_carcinogenic_when_topically_applied_to_mice_daily_for_up_to_24_months_in_the_vehicle_of_the_product_AKLIEF_Cream_at_concentrations_of_0.0005_or_0.001_w_w._The_systemic_expo" data-name="13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility
Trifarotene was not carcinogenic when topically applied to mice daily for up to 24 months in the vehicle of the product (AKLIEF Cream) at concentrations of 0.0005% or 0.001% w/w. The systemic expo" transform="translate(61 7604)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16" xml:space="preserve">13.1   Carcinogenesis, Mutagenesis, Impairment of </tspan><tspan x="0" y="35">Fertility</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="56">Trifarotene was not carcinogenic when topically applied to </tspan><tspan x="0" y="75">mice daily for up to 24 months in the vehicle of the product </tspan><tspan x="0" y="94">(AKLIEF Cream) at concentrations of 0.0005% or 0.001% w/</tspan><tspan x="0" y="113">w. The systemic exposures at the highest doses evaluated </tspan><tspan x="0" y="132">in mice were approximately 82 (males) and 99 (females) </tspan><tspan x="0" y="151">times higher than the human exposure at the MRHD of </tspan><tspan x="0" y="170">AKLIEF Cream.</tspan><tspan x="0" y="191">Trifarotene was not carcinogenic when administered orally </tspan><tspan x="0" y="210">to rats daily for up to 24 months at doses up to 0.75 mg/kg/</tspan><tspan x="0" y="229">day in males and 0.2 mg/kg/day in females. The systemic </tspan><tspan x="0" y="248">exposures at the highest doses evaluated in rats were </tspan><tspan x="0" y="267">approximately 645 (males) and 1642 (females) times </tspan><tspan x="0" y="286">higher than the human exposure at the MRHD of AKLIEF </tspan><tspan x="0" y="305">Cream.</tspan><tspan x="0" y="326">Trifarotene was negative in an in vitro bacterial reverse </tspan><tspan x="0" y="345">mutation (Ames) assay, an in vitro micronucleus assay in </tspan><tspan x="0" y="364">primary human lymphocytes, an in vitro mouse lymphoma </tspan><tspan x="0" y="383">assay with L5178Y/TK+/- cells, and an in vivo micronucleus </tspan><tspan x="0" y="402">assay in rats.</tspan><tspan x="0" y="423">Trifarotene was assessed for effects on fertility or general </tspan><tspan x="0" y="442">reproductive function in rats. Males received trifarotene via </tspan><tspan x="0" y="461">oral gavage for 4 weeks prior to mating, during mating, </tspan><tspan x="0" y="480">and up to scheduled termination (approximately 6 weeks </tspan><tspan x="0" y="499">in total), and females were treated via oral gavage for 2 </tspan><tspan x="0" y="518">weeks prior to mating through Day 7 of gestation. No </tspan><tspan x="0" y="537">adverse effects on fertility or reproductive parameters, </tspan><tspan x="0" y="556">including sperm motility and concentration, were observed </tspan><tspan x="0" y="575">at the highest doses evaluated, which resulted in systemic </tspan><tspan x="0" y="594">exposures approximately 1755 (males) and 1726 (females) </tspan><tspan x="0" y="613">times higher than the human exposure at the MRHD of </tspan><tspan x="0" y="632">AKLIEF Cream.</tspan></tspan></text>
  <text id="_14_CLINICAL_STUDIES" data-name="14  CLINICAL STUDIES" transform="translate(45 8243)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16" xml:space="preserve">14  CLINICAL STUDIES</tspan></text>
  <text id="AKLIEF_Cream_applied_once_daily_in_the_evening_was_evaluated_in_the_treatment_of_moderate_facial_and_truncal_acne_vulgaris_in_two_randomized_multicenter_parallel_group_double-blind_vehicle-controlled_trials_of_identical_design_Study_1_NCT02566369_an" data-name="AKLIEF Cream applied once daily in the evening was evaluated in the treatment of moderate facial and truncal acne vulgaris in two randomized, multicenter, parallel group, double-blind, vehicle-controlled trials of identical design, Study 1 (NCT02566369) an" transform="translate(61 8265)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="16">AKLIEF Cream applied once daily in the evening was </tspan><tspan x="0" y="35">evaluated in the treatment of moderate facial and truncal </tspan><tspan x="0" y="54">acne vulgaris in two randomized, multicenter, parallel </tspan><tspan x="0" y="73">group, double-blind, vehicle-controlled trials of identical </tspan><tspan x="0" y="92">design, Study 1 (NCT02566369) and Study 2 </tspan><tspan x="0" y="111">(NCT02556788). The trials were conducted in a total of 2420 </tspan><tspan x="0" y="130">subjects aged 9 years and older, who were treated for up </tspan><tspan x="0" y="149">to 12 weeks with either AKLIEF Cream (1214 subjects) or </tspan><tspan x="0" y="168">vehicle cream (1206 subjects). Subjects were encouraged </tspan><tspan x="0" y="187">to use a moisturizer as desired, while allowing an interval </tspan><tspan x="0" y="206">of approximately 1 hour before or after the study treatment </tspan><tspan x="0" y="225">application.</tspan><tspan x="0" y="246">Acne severity was evaluated using a 5-point Investigator’s </tspan><tspan x="0" y="265">Global Assessment (IGA) scale for the face and a 5-point </tspan><tspan x="0" y="284">Physician’s Global Assessment (PGA) scale for the trunk </tspan><tspan x="0" y="303">with moderate acne vulgaris defined as a score of 3. </tspan><tspan x="0" y="322">Overall, 87% of subjects were Caucasian and 55% were </tspan><tspan x="0" y="341">female. Thirty-four (1.4%) subjects were 9 to 11 years of age, </tspan><tspan x="0" y="360">1128 (47%) subjects were 12 to 17 years of age, and 1258 </tspan><tspan x="0" y="379">(52%) subjects were 18 years and older. All subjects had </tspan><tspan x="0" y="398">moderate acne vulgaris on the face and 99% of subjects </tspan><tspan x="0" y="417">had moderate acne vulgaris on the trunk. At baseline, </tspan><tspan x="0" y="436">subjects had between 7 and 200 (average 36) </tspan><tspan x="0" y="455">inflammatory lesions on the face and between 0 and 220 </tspan><tspan x="0" y="474">(average 38) on the trunk. Additionally, subjects had 21 to </tspan><tspan x="0" y="493">305 (average 52) non-inflammatory lesions on the face </tspan><tspan x="0" y="512">and 0 to 260 (average 46) on the trunk.</tspan><tspan x="0" y="533">Success on the IGA/PGA scale was defined as achieving a </tspan><tspan x="0" y="552">score of 0 (clear) or 1 (almost clear) and at least a 2-grade </tspan><tspan x="0" y="571">improvement from baseline. The co-primary endpoints </tspan><tspan x="0" y="590">(evaluated on the face) were the percentage of subjects </tspan><tspan x="0" y="609">achieving success on the IGA scale, the mean absolute </tspan><tspan x="0" y="628">change in facial inflammatory lesion count from baseline, </tspan><tspan x="0" y="647">and the mean absolute change in facial non-inflammatory </tspan><tspan x="0" y="666">lesion count from baseline, all evaluated at Week 12. The </tspan><tspan x="0" y="685">co-secondary endpoints (evaluated on the trunk) were the </tspan><tspan x="0" y="704">percentage of subjects achieving success on the PGA scale, </tspan><tspan x="0" y="723">the mean absolute change in truncal inflammatory lesion </tspan><tspan x="0" y="742">count from baseline, and the mean absolute change in </tspan><tspan x="0" y="761">truncal non-inflammatory lesion count from baseline, all </tspan><tspan x="0" y="780">evaluated at Week 12. Efficacy results for acne on the face </tspan><tspan x="0" y="799">and trunk after 12 weeks of treatment are presented in </tspan><tspan x="0" y="818">Tables 3 and 4 respectively.</tspan></text>
  <text id="_13_NONCLINICAL_TOXICOLOGY" data-name="13  NONCLINICAL TOXICOLOGY" transform="translate(45 7584)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16" xml:space="preserve">13  NONCLINICAL TOXICOLOGY</tspan></text>
  <text id="_12.1_Mechanism_of_Action_Trifarotene_is_an_agonist_of_retinoic_acid_receptors_RAR_with_particular_activity_at_the_gamma_subtype_of_RAR._Stimulation_of_RAR_results_in_modulation_of_target_genes_which_are_associated_with_various_processes_including_cel" data-name="12.1   Mechanism of Action
Trifarotene is an agonist of retinoic acid receptors (RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results in modulation of target genes which are associated with various processes, including cel" transform="translate(61 6573)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16" xml:space="preserve">12.1   Mechanism of Action</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="35">Trifarotene is an agonist of retinoic acid receptors (RAR), </tspan><tspan x="0" y="54">with particular activity at the gamma subtype of RAR. </tspan><tspan x="0" y="73">Stimulation of RAR results in modulation of target genes </tspan><tspan x="0" y="92">which are associated with various processes, including cell </tspan><tspan x="0" y="111">differentiation and mediation of inflammation. The exact </tspan><tspan x="0" y="130">process by which trifarotene ameliorates acne is unknown.</tspan></tspan><tspan x="0" y="149" xml:space="preserve">12.2   Pharmacodynamics</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="168">At the approved recommended dosage, AKLIEF Cream </tspan><tspan x="0" y="187">does not prolong the QT interval to any clinically relevant </tspan><tspan x="0" y="206">extent.</tspan></tspan><tspan x="0" y="225" xml:space="preserve">12.3   Pharmacokinetics</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="244">Pharmacokinetics of trifarotene was evaluated in a study </tspan><tspan x="0" y="263">involving 19 adult subjects with acne vulgaris following </tspan><tspan x="0" y="282">once daily application of AKLIEF Cream for 29 days (daily </tspan><tspan x="0" y="301">dose range 1.5 g/day to 2 g/day) to the face, shoulders, </tspan><tspan x="0" y="320">chest and upper back.</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300" text-decoration="underline"><tspan x="0" y="339">Absorption</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="358">Systemic concentrations were at steady state following 2 </tspan><tspan x="0" y="377">weeks of treatment and were quantifiable in 7 subjects. </tspan><tspan x="0" y="396">Steady state Cmax ranged from below the limit of </tspan><tspan x="0" y="415">quantification (less than 5 pg/mL) to 10 pg/mL and </tspan><tspan x="0" y="434">AUC0-24h ranged from 75 to 104 pg.h/mL in adults. No </tspan><tspan x="0" y="453">drug accumulation is expected with long-term use.</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300" text-decoration="underline"><tspan x="0" y="472">Distribution</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="491">Plasma protein binding is approximately 99.9%.</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300" text-decoration="underline"><tspan x="0" y="510">Elimination</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="529">The terminal half-life ranged from 2 to 9 hours.</tspan></tspan><tspan font-family="SofiaProCondensed-Lightitalic, Sofia Pro Condensed" font-weight="300" font-style="italic"><tspan x="0" y="548">Metabolism</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="567">Trifarotene is primarily metabolized by CYP2C9, CYP3A4, </tspan><tspan x="0" y="586">CYP2C8, and to a lesser extent by CYP2B6 in vitro.</tspan></tspan><tspan font-family="SofiaProCondensed-Lightitalic, Sofia Pro Condensed" font-weight="300" font-style="italic"><tspan x="0" y="605">Excretion</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="624">Trifarotene is primarily excreted by the feces.</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300" text-decoration="underline"><tspan x="0" y="643">Specific Populations</tspan></tspan><tspan font-family="SofiaProCondensed-Lightitalic, Sofia Pro Condensed" font-weight="300" font-style="italic"><tspan x="0" y="662">Pediatric Patients</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="681">Steady state Cmax ranged from less than 5 pg/mL to 9 pg/</tspan><tspan x="0" y="700">mL and AUC0-24h ranged from 89 to 106 pg.h/mL in </tspan><tspan x="0" y="719">pediatrics (10 to 17-years-old). Steady state conditions </tspan><tspan x="0" y="738">were achieved in patients following 2 weeks of topical </tspan><tspan x="0" y="757">administration. No drug accumulation is expected with </tspan><tspan x="0" y="776">long-term use.</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300" text-decoration="underline"><tspan x="0" y="795">Drug Interactions Studies</tspan></tspan><tspan font-family="SofiaProCondensed-Lightitalic, Sofia Pro Condensed" font-weight="300" font-style="italic"><tspan x="0" y="814">Clinical Studies and Model-Based Approaches</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="833">No clinically significant differences in the </tspan><tspan x="0" y="852">pharmacokinetics of trifarotene were predicted when used </tspan><tspan x="0" y="871">concomitantly with fluconazole (a moderate CYP2C9 and </tspan><tspan x="0" y="890">CYP3A inhibitor).</tspan></tspan><tspan font-family="SofiaProCondensed-Lightitalic, Sofia Pro Condensed" font-weight="300" font-style="italic"><tspan x="0" y="909">In Vitro Studies</tspan><tspan x="0" y="928">Cytochrome P450 (CYP) Enzymes:</tspan><tspan y="928" xml:space="preserve" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-style="normal"> AKLIEF Cream is not </tspan><tspan x="0" y="947" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-style="normal">expected to inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and </tspan><tspan x="0" y="966" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-style="normal">3A4, or induce CYP1A2, 2B6, and 3A4.</tspan><tspan x="0" y="985">Transporter Systems: </tspan><tspan y="985" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-style="normal">AKLIEF Cream is not expected to </tspan><tspan x="0" y="1004" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-style="normal">inhibit MATE, OATP, OAT, OCT, BCRP, P-gp, BSEP, or MPR.</tspan></tspan></text>
  <text id="_16_HOW_SUPPLIED_STORAGE_AND_HANDLING" data-name="16  HOW SUPPLIED/STORAGE AND HANDLING" transform="translate(45 9930)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16" xml:space="preserve">16  HOW SUPPLIED/STORAGE AND HANDLING</tspan></text>
  <text id="AKLIEF_Cream_0.005_is_provided_as_a_white_cream_supplied_in_the_following_packaging_configurations_with_corresponding_NDC_numbers:_30-gram_pump_NDC_0299-5935-30_45-gram_pump_NDC_0299-5935-45_75-gram_pump_NDC_0299-5935-75_Storage_and_Handling_" data-name="AKLIEF Cream, 0.005% is provided as a white cream supplied in the following packaging configurations with corresponding NDC numbers:
•   30-gram pump    NDC 0299-5935-30
•   45-gram pump    NDC 0299-5935-45
•   75-gram pump    NDC 0299-5935-75
Storage and Handling
" transform="translate(61 9951)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="16">AKLIEF Cream, 0.005% is provided as a white cream </tspan><tspan x="0" y="35">supplied in the following packaging configurations with </tspan><tspan x="0" y="54">corresponding NDC numbers:</tspan><tspan x="0" y="73" xml:space="preserve">•   30-gram pump  NDC 0299-5935-30</tspan><tspan x="0" y="92" xml:space="preserve">•   45-gram pump   NDC 0299-5935-45</tspan><tspan x="0" y="111" xml:space="preserve">•   75-gram pump  NDC 0299-5935-75</tspan><tspan text-decoration="underline"><tspan x="0" y="130">Storage and Handling</tspan></tspan><tspan x="0" y="149">- Store at 20 to 25˚C (68 to 77˚F) with excursions permitted </tspan><tspan x="0" y="168" xml:space="preserve">   to 15°to 30°C (59° to 86°F).</tspan><tspan x="0" y="187">- Keep away from heat.</tspan><tspan x="0" y="206">- Keep out of reach of children.</tspan></text>
  <text id="See_FDA-approved_patient_labeling_Patient_Information_._Advise_the_patient_to:_Cleanse_the_area_to_be_treated_pat_dry._Apply_AKLIEF_Cream_as_a_thin_layer_once_daily_in_the_evening_to_the_face_avoiding_the_eyes_lips_nasolabial_folds_" data-name="See FDA-approved patient labeling (Patient Information).
Advise the patient to:
•   Cleanse the area to be treated; pat dry. Apply AKLIEF   
     Cream as a thin layer once daily in the evening to the 
     face, avoiding the eyes, lips, nasolabial folds, " transform="translate(61 10200)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="16">See FDA-approved patient labeling (Patient Information).</tspan><tspan x="0" y="35">Advise the patient to:</tspan><tspan x="0" y="54" xml:space="preserve">•   Cleanse the area to be treated; pat dry. Apply AKLIEF   </tspan><tspan x="0" y="73" xml:space="preserve">     Cream as a thin layer once daily in the evening to the </tspan><tspan x="0" y="92" xml:space="preserve">     face, avoiding the eyes, lips, nasolabial folds, and </tspan><tspan x="0" y="111" xml:space="preserve">     mucous membranes. A thin layer of AKLIEF Cream may </tspan><tspan x="0" y="130" xml:space="preserve">     also be applied to the chest, shoulders, and back.</tspan><tspan x="0" y="149" xml:space="preserve">•   Avoid applying AKLIEF Cream to damaged skin (such as </tspan><tspan x="0" y="168" xml:space="preserve">     cuts, abrasions), eczematous areas, and sunburned </tspan><tspan x="0" y="187" xml:space="preserve">     skin.</tspan><tspan x="0" y="206" xml:space="preserve">•   Reduce the risk of such irritation, use a moisturizer from </tspan><tspan x="0" y="225" xml:space="preserve">     the start of treatment, and, if appropriate, reduce the </tspan><tspan x="0" y="244" xml:space="preserve">     frequency of application of AKLIEF Cream or suspend </tspan><tspan x="0" y="263" xml:space="preserve">     use temporarily. AKLIEF Cream may cause irritation such </tspan><tspan x="0" y="282" xml:space="preserve">     as erythema, scaling, dryness, and stinging or burning.</tspan><tspan x="0" y="301" xml:space="preserve">•   Minimize exposure to sunlight, including sunlamps and  </tspan><tspan x="0" y="320" xml:space="preserve">     phototherapy devices.</tspan><tspan x="0" y="339" xml:space="preserve">•   Use sunscreen products and protective apparel (e.g., </tspan><tspan x="0" y="358" xml:space="preserve">     hat) over treated areas when exposure to sunlight </tspan><tspan x="0" y="377" xml:space="preserve">     cannot be avoided.</tspan><tspan x="0" y="396" xml:space="preserve">•   Avoid concomitant use of other potentially irritating </tspan><tspan x="0" y="415" xml:space="preserve">     topical products (medicated or not).</tspan><tspan x="0" y="434" xml:space="preserve">•   Use AKLIEF Cream on the smallest area of skin and for </tspan><tspan x="0" y="453" xml:space="preserve">     the shortest duration possible while breastfeeding. </tspan><tspan x="0" y="472" xml:space="preserve">     Advise breastfeeding women not to apply AKLIEF Cream </tspan><tspan x="0" y="491" xml:space="preserve">     directly to the nipple and areola to avoid direct infant </tspan><tspan x="0" y="510" xml:space="preserve">     exposure.</tspan></text>
  <text id="_17_PATIENT_COUNSELING_INFORMATION" data-name="17  PATIENT COUNSELING INFORMATION" transform="translate(45 10180)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16" xml:space="preserve">17  PATIENT COUNSELING INFORMATION</tspan></text>
  <text id="_1_INDICATIONS_AND_USAGE_AKLIEF_Cream_is_a_retinoid_indicated_for_the_topical_treatment_of_acne_vulgaris_in_patients_9_years_of_age_and_older._2_DOSAGE_AND_ADMINISTRATION_Apply_a_thin_layer_of_AKLIEF_Cream_to_the_affected_areas_" data-name="1   INDICATIONS AND USAGE
     AKLIEF Cream is a retinoid indicated for the topical 
     treatment of acne vulgaris in patients 9 years of age and 
     older.
2   DOSAGE AND ADMINISTRATION
     Apply a thin layer of AKLIEF Cream to the affected areas 
  " transform="translate(45 1711)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16" xml:space="preserve">1   INDICATIONS AND USAGE</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="35" xml:space="preserve">     AKLIEF Cream is a retinoid indicated for the topical </tspan><tspan x="0" y="54" xml:space="preserve">     treatment of acne vulgaris in patients 9 years of age and </tspan><tspan x="0" y="73" xml:space="preserve">     older.</tspan></tspan><tspan x="0" y="92" xml:space="preserve">2   DOSAGE AND ADMINISTRATION</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="111" xml:space="preserve">     Apply a thin layer of AKLIEF Cream to the affected areas </tspan><tspan x="0" y="130" xml:space="preserve">     once daily, in the evening, on clean and dry skin.</tspan><tspan x="0" y="149" xml:space="preserve">     •   One pump actuation should be enough to cover the face </tspan><tspan x="0" y="168" xml:space="preserve">          (i.e., forehead, cheeks, nose, and chin).</tspan><tspan x="0" y="187" xml:space="preserve">     •   Two actuations of the pump should be enough to cover </tspan><tspan x="0" y="206" xml:space="preserve">          the upper trunk (i.e., reachable upper back, shoulders </tspan><tspan x="0" y="225" xml:space="preserve">          and chest). One additional pump actuation may be used </tspan><tspan x="0" y="244" xml:space="preserve">          for middle and lower back if acne is present.</tspan><tspan x="0" y="263" xml:space="preserve">     The use of a moisturizer is recommended as frequently as  </tspan><tspan x="0" y="282" xml:space="preserve">     needed from the initiation of treatment.</tspan><tspan x="0" y="301" xml:space="preserve">     Avoid contact with the eyes, lips, paranasal creases,</tspan><tspan x="0" y="320" xml:space="preserve">     mucous membranes.</tspan><tspan x="0" y="339" xml:space="preserve">     AKLIEF Cream is for topical use only. Not for oral,</tspan><tspan x="0" y="358" xml:space="preserve">     ophthalmic, or intravaginal use.</tspan></tspan><tspan x="0" y="377" xml:space="preserve">3   DOSAGE FORMS AND STRENGTHS</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="396" xml:space="preserve">     Cream: 0.005%. Each gram of AKLIEF Cream contains 50 </tspan><tspan x="0" y="415" xml:space="preserve">     mcg of trifarotene in a white cream.</tspan></tspan><tspan x="0" y="434" xml:space="preserve">4   CONTRAINDICATIONS</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="453" xml:space="preserve">     None</tspan></tspan><tspan x="0" y="472" xml:space="preserve">5   WARNINGS AND PRECAUTIONS</tspan><tspan x="0" y="491" xml:space="preserve">     5.1   Skin Irritation</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="510" xml:space="preserve">     Patients using AKLIEF Cream may experience erythema, </tspan><tspan x="0" y="529" xml:space="preserve">     scaling, dryness, and stinging/burning. Maximum severity </tspan><tspan x="0" y="548" xml:space="preserve">     of these reactions typically occurred within the first 4 weeks </tspan><tspan x="0" y="567" xml:space="preserve">     of treatment, and severity decreased with continued use of </tspan><tspan x="0" y="586" xml:space="preserve">     the medication. Depending upon the severity of these </tspan><tspan x="0" y="605" xml:space="preserve">     adverse reactions, instruct patients to use a moisturizer, </tspan><tspan x="0" y="624" xml:space="preserve">     reduce the frequency of application of AKLIEF Cream, or </tspan><tspan x="0" y="643" xml:space="preserve">     suspend use temporarily. If severe reactions persist the </tspan><tspan x="0" y="662" xml:space="preserve">     treatment may be discontinued.</tspan><tspan x="0" y="681" xml:space="preserve">     Avoid application of AKLIEF Cream to cuts, abrasions, or </tspan><tspan x="0" y="700" xml:space="preserve">     eczematous or sunburned skin. Use of “waxing” as a </tspan><tspan x="0" y="719" xml:space="preserve">     depilatory method should be avoided on skin treated with </tspan><tspan x="0" y="738" xml:space="preserve">     AKLIEF Cream.</tspan></tspan><tspan x="0" y="757" xml:space="preserve">     5.2   Ultraviolet Light and Environmental Exposure</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="776" xml:space="preserve">     Minimize unprotected exposure to ultraviolet rays </tspan><tspan x="0" y="795" xml:space="preserve">     (including sunlight and sunlamps) during treatment with </tspan><tspan x="0" y="814" xml:space="preserve">     AKLIEF Cream. Warn patients who normally experience </tspan><tspan x="0" y="833" xml:space="preserve">     high levels of sun exposure and those with inherent </tspan><tspan x="0" y="852" xml:space="preserve">     sensitivity to sun to exercise caution. Use of sunscreen </tspan><tspan x="0" y="871" xml:space="preserve">     products and protective clothing over treated areas is </tspan><tspan x="0" y="890" xml:space="preserve">     recommended when exposure cannot be avoided.</tspan></tspan><tspan x="0" y="909" xml:space="preserve">6   ADVERSE REACTIONS</tspan><tspan x="0" y="928" xml:space="preserve">     6.1   Clinical trials experience</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="947" xml:space="preserve">     Because clinical trials are conducted under widely varying </tspan><tspan x="0" y="966" xml:space="preserve">     conditions, adverse reaction rates observed in the clinical </tspan><tspan x="0" y="985" xml:space="preserve">     trials of a drug cannot be directly compared with rates in </tspan><tspan x="0" y="1004" xml:space="preserve">     the clinical trials of another drug and may not reflect rates </tspan><tspan x="0" y="1023" xml:space="preserve">     observed in practice. In the three Phase 3 clinical trials, a </tspan><tspan x="0" y="1042" xml:space="preserve">     total of 1673 subjects with acne vulgaris on the face and </tspan><tspan x="0" y="1061" xml:space="preserve">     trunk, 9 years and older were exposed to AKLIEF Cream. </tspan><tspan x="0" y="1080" xml:space="preserve">     Of these, 1220 subjects were treated once daily for up to 12 </tspan><tspan x="0" y="1099" xml:space="preserve">     weeks and 453 were treated once daily for up to 1 year.</tspan><tspan x="0" y="1118"></tspan><tspan x="0" y="1137" xml:space="preserve">     Adverse reactions reported in the 2 randomized, double-</tspan><tspan x="0" y="1156" xml:space="preserve">     blind, vehicle-controlled 12-week clinical trials in ≥1.0% of </tspan><tspan x="0" y="1175" xml:space="preserve">     subjects treated with AKLIEF Cream (and for which the rate </tspan><tspan x="0" y="1194" xml:space="preserve">     exceeded the rate for vehicle), as well as the corresponding </tspan><tspan x="0" y="1213" xml:space="preserve">     rates reported in subjects treated with the vehicle cream </tspan><tspan x="0" y="1232" xml:space="preserve">     are presented in Table 1.</tspan></tspan></text>
  <text id="FULL_PRESCRIBING_INFORMATION" data-name="FULL PRESCRIBING INFORMATION" transform="translate(0 1686)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="120.496" y="16">FULL PRESCRIBING INFORMATION</tspan></text>
  <text id="Table_1._Adverse_Reactions_Occurring_in_1.0_of_Subjects_with_Acne_Vulgaris_of_the_Face_and_Trunk_in_the_Two_12-week_Phase_3_Clinical_Trials" data-name="Table 1. Adverse Reactions Occurring in ≥ 1.0% of Subjects with Acne Vulgaris of the Face and Trunk in the Two 12-week Phase 3 Clinical Trials" transform="translate(45 2975)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16">Table 1. Adverse Reactions Occurring in ≥ 1.0% of Subjects </tspan><tspan x="0" y="35">with Acne Vulgaris of the Face and Trunk in the Two 12-week </tspan><tspan x="0" y="54">Phase 3 Clinical Trials</tspan></text>
  <text id="Table_2._Application_Site_Tolerability_Reactions_at_Any_Post_Baseline_Visit" data-name="Table 2. Application Site Tolerability Reactions at Any Post Baseline Visit" transform="translate(45 3735.074)" fill="#1a1818" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700" letter-spacing="-0.01em"><tspan x="0" y="16">Table 2. Application Site Tolerability Reactions at Any Post </tspan><tspan x="0" y="35">Baseline Visit</tspan></text>
  <text id="Table_3._Acne_of_the_Face_Efficacy_Results_at_Week_12_Intent-to-Treat_Multiple_Imputation_" data-name="Table 3. Acne of the Face Efficacy Results at Week 12 (Intent-to-Treat; Multiple Imputation)" transform="translate(45 9101)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16">Table 3. Acne of the Face Efficacy Results at Week 12 </tspan><tspan x="0" y="35">(Intent-to-Treat; Multiple Imputation)</tspan></text>
  <text id="Table_4._Acne_of_the_Trunk_Efficacy_Results_at_Week_12_Intent-to-Treat_on_the_Trunk_Multiple_Imputation_" data-name="Table 4. Acne of the Trunk Efficacy Results at Week 12 (Intent-to-Treat on the Trunk; Multiple Imputation)" transform="translate(45 9516)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16">Table 4. Acne of the Trunk Efficacy Results at Week 12 </tspan><tspan x="0" y="35">(Intent-to-Treat on the Trunk; Multiple Imputation)</tspan></text>
  <text id="Important:_AKLIEF_Cream_is_for_use_on_the_skin_only._Do_not_use_AKLIEF_Cream_in_your_mouth_eyes_or_vagina._What_is_AKLIEF_Cream_AKLIEF_Cream_is_a_prescription_medicine_used_on_the_skin_topical_to_treat_acne_vulgaris_in_people_9_years_of_age_and_olde" data-name="Important: AKLIEF Cream is for use on the skin only.  Do not use AKLIEF Cream in your mouth, eyes, or vagina.

What is AKLIEF Cream?
AKLIEF Cream is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 9 years of age and olde" transform="translate(45 10807)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16">Important:</tspan><tspan y="16" xml:space="preserve" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"> AKLIEF Cream is for use on the skin only.  Do not </tspan><tspan x="0" y="35" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">use AKLIEF Cream in your mouth, eyes, or vagina.</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="54"></tspan></tspan><tspan x="0" y="73">What is AKLIEF Cream?</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="92">AKLIEF Cream is a prescription medicine used on the skin </tspan><tspan x="0" y="111">(topical) to treat acne vulgaris in people 9 years of age and </tspan><tspan x="0" y="130">older.</tspan><tspan x="0" y="149">It is not known if AKLIEF Cream is safe and effective in children </tspan><tspan x="0" y="168">younger than 9 years old.</tspan><tspan x="0" y="187"></tspan></tspan><tspan x="0" y="206">Before using AKLIEF Cream, tell your healthcare provider </tspan><tspan x="0" y="225">about all of your medical conditions, including if you:</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="244" xml:space="preserve">•   have skin problems, including eczema, cuts or sunburn</tspan><tspan x="0" y="263" xml:space="preserve">•   are pregnant or planning to become pregnant. It is not </tspan><tspan x="0" y="282" xml:space="preserve">     known if AKLIEF Cream will harm your unborn baby.</tspan><tspan x="0" y="301" xml:space="preserve">•   are breastfeeding or plan to breastfeed. It is not known if </tspan><tspan x="0" y="320" xml:space="preserve">     AKLIEF Cream passes into your breast milk. Breastfeeding </tspan><tspan x="0" y="339" xml:space="preserve">     women should use AKLIEF Cream on the smallest area of </tspan><tspan x="0" y="358" xml:space="preserve">     skin and for the shortest time needed while breastfeeding. </tspan><tspan x="0" y="377" xml:space="preserve">     Do not apply AKLIEF Cream to the nipple and areola to </tspan><tspan x="0" y="396" xml:space="preserve">     avoid contact with your baby.</tspan></tspan><tspan x="0" y="415">Tell your healthcare provider about all the medicines you </tspan><tspan x="0" y="434">take,</tspan><tspan y="434" xml:space="preserve" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"> including prescription and over-the-counter medicines, </tspan><tspan x="0" y="453" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">vitamins and herbal supplements.</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="472">Especially tell your healthcare provider if you use any other </tspan><tspan x="0" y="491">medicine for acne.</tspan><tspan x="0" y="510"></tspan></tspan><tspan x="0" y="529">How should I use AKLIEF Cream?</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="548" xml:space="preserve">•   Use AKLIEF Cream exactly as your healthcare provider tells </tspan><tspan x="0" y="567" xml:space="preserve">     you to use it. Apply a thin layer of AKLIEF Cream over the </tspan><tspan x="0" y="586" xml:space="preserve">     affected areas 1 time each day, in the evening.</tspan></tspan><tspan x="0" y="605">Applying AKLIEF Cream:</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="624" xml:space="preserve">•   Wash the area where the cream will be applied and pat </tspan><tspan x="0" y="643" xml:space="preserve">     dry.</tspan><tspan x="0" y="662" xml:space="preserve">•   If you receive a sample tube of AKLIEF Cream, follow your </tspan><tspan x="0" y="681" xml:space="preserve">     healthcare provider’s instructions about how much to </tspan><tspan x="0" y="700" xml:space="preserve">     apply.</tspan><tspan x="0" y="719" xml:space="preserve">•   AKLIEF Cream comes in a pump.</tspan><tspan x="0" y="738" xml:space="preserve">    -   Press down on (depress) the pump 1 time to dispense a </tspan><tspan x="0" y="757" xml:space="preserve">         small amount of AKLIEF Cream and spread a thin layer </tspan><tspan x="0" y="776" xml:space="preserve">         over your face (forehead, cheeks, nose, and chin). Avoid </tspan><tspan x="0" y="795" xml:space="preserve">         contact with your eyes, lips, mouth, and the corners of </tspan><tspan x="0" y="814" xml:space="preserve">         your nose.</tspan><tspan x="0" y="833" xml:space="preserve">    -   Press down on the pump 2 times to dispense enough </tspan><tspan x="0" y="852" xml:space="preserve">         AKLIEF Cream to apply a thin layer to cover your upper </tspan><tspan x="0" y="871" xml:space="preserve">         trunk (the area of your upper back that you can reach, </tspan><tspan x="0" y="890" xml:space="preserve">         shoulders, and chest). One more pump may be used to </tspan><tspan x="0" y="909" xml:space="preserve">         apply a thin layer of AKLIEF Cream to your middle and </tspan><tspan x="0" y="928" xml:space="preserve">         lower back, if acne is present.</tspan><tspan x="0" y="947" xml:space="preserve">•   When you begin treatment with AKLIEF Cream, you should </tspan><tspan x="0" y="966" xml:space="preserve">     begin applying a moisturizer on your skin as often as </tspan><tspan x="0" y="985" xml:space="preserve">     needed. </tspan><tspan y="985" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700">See “Local skin irritation”</tspan><tspan y="985" xml:space="preserve"> below.</tspan><tspan x="0" y="1004"></tspan></tspan><tspan x="0" y="1023">What should I avoid while using AKLIEF Cream?</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="1042" xml:space="preserve">•   Minimize exposure to sunlight. You should avoid using </tspan><tspan x="0" y="1061" xml:space="preserve">     sunlamps, tanning beds, and ultraviolet light during </tspan><tspan x="0" y="1080" xml:space="preserve">     treatment with AKLIEF Cream. </tspan><tspan x="0" y="1099" xml:space="preserve">     If you have to be in sunlight or are sensitive to sunlight, use </tspan><tspan x="0" y="1118" xml:space="preserve">     a sunscreen with a SPF (sun protection factor) of 15 or </tspan><tspan x="0" y="1137" xml:space="preserve">     more, and wear protective clothing and a wide-brimmed </tspan><tspan x="0" y="1156" xml:space="preserve">     hat to cover the treated areas.</tspan><tspan x="0" y="1175" xml:space="preserve">•   Avoid using AKLIEF Cream on skin areas with cuts, </tspan><tspan x="0" y="1194" xml:space="preserve">    abrasions, eczema, or on sunburned skin.</tspan><tspan x="0" y="1213" xml:space="preserve">•   Avoid using skin products that may dry or irritate your skin, </tspan><tspan x="0" y="1232" xml:space="preserve">    such as: </tspan><tspan x="0" y="1251" xml:space="preserve">    -   medicated or abrasive soaps and cleansers</tspan><tspan x="0" y="1270" xml:space="preserve">    -   soaps, cleansers, and cosmetics that have strong skin </tspan><tspan x="0" y="1289" xml:space="preserve">         drying effects</tspan><tspan x="0" y="1308" xml:space="preserve">    -   products that contain high amounts of alcohol</tspan><tspan x="0" y="1327" xml:space="preserve">•   Avoid the use of “waxing” as a hair removal method on skin </tspan><tspan x="0" y="1346" xml:space="preserve">    treated with AKLIEF Cream.</tspan><tspan x="0" y="1365"></tspan></tspan><tspan x="0" y="1384">What are the possible side effects of AKLIEF Cream?</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="1403">AKLIEF Cream may cause serious side effects including:</tspan><tspan x="0" y="1422" xml:space="preserve">•   </tspan><tspan y="1422" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700">Local skin irritation.</tspan><tspan y="1422" xml:space="preserve"> Local skin reactions are common with </tspan><tspan x="0" y="1441" xml:space="preserve">     AKLIEF Cream, are most likely to happen during the first 4 </tspan><tspan x="0" y="1460" xml:space="preserve">     weeks of treatment and may decrease with continued use </tspan><tspan x="0" y="1479" xml:space="preserve">     of AKLIEF Cream. Signs and symptoms of local skin </tspan><tspan x="0" y="1498" xml:space="preserve">     reactions include:</tspan><tspan x="0" y="1517" xml:space="preserve">      -   redness      - dryness</tspan><tspan x="0" y="1536" xml:space="preserve">      -   scaling       - stinging or burning</tspan><tspan x="0" y="1555" xml:space="preserve">     To help reduce your risk of developing these local skin </tspan><tspan x="0" y="1574" xml:space="preserve">     reactions, when you begin treatment with AKLIEF Cream, </tspan><tspan x="0" y="1593" xml:space="preserve">     you should begin applying a moisturizer on your skin as </tspan><tspan x="0" y="1612" xml:space="preserve">     often as needed. </tspan><tspan x="0" y="1631" xml:space="preserve">     Tell your healthcare provider if you develop symptoms of a </tspan><tspan x="0" y="1650" xml:space="preserve">     local skin reaction. Your doctor may tell you to use AKLIEF </tspan><tspan x="0" y="1669" xml:space="preserve">     Cream less often, or temporarily, or permanently stop your </tspan><tspan x="0" y="1688" xml:space="preserve">     treatment with AKLIEF Cream.</tspan><tspan x="0" y="1707" xml:space="preserve">     The most common side effects of AKLIEF Cream include: </tspan><tspan x="0" y="1726" xml:space="preserve">     itching and sunburn. </tspan><tspan y="1726" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700">See “What should I avoid while using </tspan></tspan><tspan x="0" y="1745" xml:space="preserve">      AKLIEF Cream”.</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="1764" xml:space="preserve">     These are not all the possible side effects of AKLIEF Cream. </tspan><tspan x="0" y="1783" xml:space="preserve">     For more information, ask your healthcare provider or </tspan><tspan x="0" y="1802" xml:space="preserve">     pharmacist.</tspan><tspan x="0" y="1821" xml:space="preserve">     Call your doctor for medical advice about side effects. You </tspan><tspan x="0" y="1840" xml:space="preserve">     may report side effects to FDA at 1-800-FDA-1088.</tspan><tspan x="0" y="1859" xml:space="preserve">     You may also report side effects to GALDERMA </tspan><tspan x="0" y="1878" xml:space="preserve">     LABORATORIES, L.P. at 1-866-735-4137.</tspan><tspan x="0" y="1897"></tspan></tspan><tspan x="0" y="1916">How should I store AKLIEF Cream?</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="1935">• Store AKLIEF Cream at room temperature, 68° to 77° F (20° to </tspan><tspan x="0" y="1954" xml:space="preserve">   25°C).</tspan><tspan x="0" y="1973">• Keep AKLIEF Cream away from heat.</tspan><tspan x="0" y="1992">• If you receive a sample tube of AKLIEF Cream from your </tspan><tspan x="0" y="2011">healthcare provider, keep the tube tightly closed.</tspan></tspan><tspan x="0" y="2030">Keep AKLIEF Cream and all medicines out of the reach of </tspan><tspan x="0" y="2049">children.</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="2068"></tspan></tspan><tspan x="0" y="2087">General information about the safe and effective use of </tspan><tspan x="0" y="2106">AKLIEF Cream.</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="2125">Medicines are sometimes prescribed for purposes other than </tspan><tspan x="0" y="2144">those listed in a Patient Information Leaflet. Do not use AKLIEF </tspan><tspan x="0" y="2163">Cream for a condition for which it was not prescribed. Do not </tspan><tspan x="0" y="2182">give AKLIEF Cream to other people, even if they have the </tspan><tspan x="0" y="2201">same symptoms you have. It may harm them. You can ask </tspan><tspan x="0" y="2220">your pharmacist or healthcare provider for information about </tspan><tspan x="0" y="2239">AKLIEF Cream that is written for health professionals.</tspan><tspan x="0" y="2258"></tspan></tspan><tspan x="0" y="2277">What are the ingredients in AKLIEF Cream?</tspan><tspan x="0" y="2296">Active ingredient: </tspan><tspan y="2296" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">trifarotene</tspan><tspan x="0" y="2315">Inactive ingredients:</tspan><tspan y="2315" xml:space="preserve" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"> allantoin, copolymer of acrylamide and </tspan><tspan x="0" y="2334" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">sodium acryloyldimethyltaurate, dispersion 40% in </tspan><tspan x="0" y="2353" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">isohexadecane, cyclomethicone, 5% ethanol, medium-chain </tspan><tspan x="0" y="2372" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">triglycerides, phenoxyethanol, propylene glycol, purified </tspan><tspan x="0" y="2391" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">water.</tspan></text>
  <line id="Line_91" data-name="Line 91" x2="340" transform="translate(45.5 10741.026)" fill="none" stroke="#1a1818" stroke-width="1"/>
  <text id="Patient_Information_AKLIEF_trifarotene_cream" data-name="Patient Information 
AKLIEF® (trifarotene) cream" transform="translate(66 10758)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="101.416" y="16">Patient Information </tspan><tspan x="76.088" y="35">AKLIEF® (trifarotene) cream</tspan></text>
  <text id="_-_WARNINGS_AND_PRECAUTIONS_-" data-name="——-—————WARNINGS AND PRECAUTIONS————–———-" transform="translate(45 592)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="1.552" y="16">——-—————WARNINGS AND PRECAUTIONS————–———-</tspan></text>
  <text id="_Skin_irritation:_Erythema_scaling_dryness_and_stinging_burning_may_be_experienced_with_use_of_AKLIEF_Cream._Use_a_moisturizer_from_the_initiation_of_treatment_and_if_appropriate_reduce_the_frequency_of_application_of_AKLIEF_" data-name="•   Skin irritation: Erythema, scaling, dryness, and stinging/
     burning may be experienced with use of AKLIEF Cream. 
     Use a moisturizer from the initiation of treatment, and, if 
     appropriate, reduce the frequency of application of AKLIEF 
   " transform="translate(45 624)" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="16" xml:space="preserve">•   Skin irritation: Erythema, scaling, dryness, and stinging/</tspan><tspan x="0" y="35" xml:space="preserve">     burning may be experienced with use of AKLIEF Cream. </tspan><tspan x="0" y="54" xml:space="preserve">     Use a moisturizer from the initiation of treatment, and, if </tspan><tspan x="0" y="73" xml:space="preserve">     appropriate, reduce the frequency of application of AKLIEF </tspan><tspan x="0" y="92" xml:space="preserve">     Cream, suspend or discontinue use. (5.1)</tspan><tspan x="0" y="111" xml:space="preserve">•   Ultraviolet Light and Environmental Exposure: Minimize </tspan><tspan x="0" y="130" xml:space="preserve">     exposure to sunlight and sunlamps. Use sunscreen and </tspan><tspan x="0" y="149" xml:space="preserve">     protective clothing over treated areas when exposure </tspan><tspan x="0" y="168" xml:space="preserve">     cannot be avoided. (5.2)</tspan><tspan font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="187"></tspan><tspan x="0" y="206">—————-————ADVERSE REACTIONS——————————</tspan></tspan><tspan x="0" y="225">Most common adverse reactions (incidence ≥ 1%) in patients </tspan><tspan x="0" y="244">treated with AKLIEF Cream were application site irritation, </tspan><tspan x="0" y="263">application site pruritus, and sunburn (6).</tspan><tspan x="0" y="282"></tspan><tspan font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="301">To report SUSPECTED ADVERSE REACTIONS, contact </tspan><tspan x="0" y="320">Galderma Laboratories, L.P. at 1-866-735-4137 or </tspan><tspan x="0" y="339">FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</tspan><tspan x="0" y="358">See 17 for PATIENT COUNSELING INFORMATION </tspan><tspan x="0" y="377" xml:space="preserve">and FDA-approved patient labeling.                       </tspan><tspan x="0" y="396">Revised: 10/2019</tspan><tspan x="0" y="415"></tspan></tspan></text>
  <text id="_11_DESCRIPTION_12_CLINICAL_PHARMACOLOGY_12.1_Mechanism_of_Action_12.2_Pharmacodynamics_12.3_Pharmacokinetics_13_NONCLINICAL_TOXICOLOGY_13.1_Carcinogenesis_Mutagenesis_Impairment_of_Fertility_14_CLINICAL_STUDIES_16_HOW_SUPPLIED_STORAGE_AND" data-name="11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action
    12.2 Pharmacodynamics
    12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND" transform="translate(45 1402)" font-size="16" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="0" y="16">11 DESCRIPTION</tspan><tspan x="0" y="35">12 CLINICAL PHARMACOLOGY</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="54" xml:space="preserve">    12.1 Mechanism of Action</tspan><tspan x="0" y="73" xml:space="preserve">    12.2 Pharmacodynamics</tspan><tspan x="0" y="92" xml:space="preserve">    12.3 Pharmacokinetics</tspan></tspan><tspan x="0" y="111">13 NONCLINICAL TOXICOLOGY</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="130" xml:space="preserve">    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</tspan></tspan><tspan x="0" y="149">14 CLINICAL STUDIES</tspan><tspan x="0" y="168">16 HOW SUPPLIED/STORAGE AND HANDLING</tspan><tspan x="0" y="187">17 PATIENT COUNSELING INFORMATION</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="206">*Sections or subsections omitted from the</tspan><tspan x="0" y="225">full prescribing information are not listed.</tspan></tspan></text>
  <g id="Group_28" data-name="Group 28" transform="translate(28 -5)">
    <g id="Group_1" data-name="Group 1" transform="translate(17 3052.623)">
      <rect id="Rectangle_1" data-name="Rectangle 1" width="340.858" height="107.721" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
      <line id="Line_1" data-name="Line 1" x2="340.858" transform="translate(0 80.791)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
      <line id="Line_2" data-name="Line 2" x2="340.858" transform="translate(0 53.861)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
      <line id="Line_3" data-name="Line 3" x2="340.858" transform="translate(0 26.93)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
      <line id="Line_4" data-name="Line 4" y2="107.721" transform="translate(227.239)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
      <line id="Line_5" data-name="Line 5" y2="107.721" transform="translate(113.619)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.48"/>
    </g>
    <text id="Preferred_Term_Application_site_irritation_Application_site_pruritus_Sunburn" data-name="Preferred Term
Application site irritation
Application site pruritus
Sunburn" transform="translate(17 3056.335)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="24.523" y="12">Preferred Term</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="6.355" y="38">Application site irritation</tspan><tspan x="7.813" y="64">Application site pruritus</tspan><tspan x="39.049" y="90">Sunburn</tspan></tspan></text>
    <text id="AKLIEF_Cream_N_1220_91_7.5_29_2.4_32_2.6_" data-name="AKLIEF Cream (N= 1220)
91 (7.5)
29 (2.4)
32 (2.6)" transform="translate(130.548 3056.335)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="5.99" y="12">AKLIEF Cream (N= 1220)</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="42.98" y="38">91 (7.5)</tspan><tspan x="41.858" y="64">29 (2.4)</tspan><tspan x="42.134" y="90">32 (2.6)</tspan></tspan></text>
    <text id="Vehicle_Cream_N_1200_4_0.3_10_0.8_6_0.5_" data-name="Vehicle Cream (N=1200)
4 (0.3)
10 (0.8)
6 (0.5)" transform="translate(244 3056.335)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="8.019" y="12">Vehicle Cream (N=1200)</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="46.155" y="38">4 (0.3)</tspan><tspan x="44.277" y="64">10 (0.8)</tspan><tspan x="45.849" y="90">6 (0.5)</tspan></tspan></text>
  </g>
  <g id="Group_8" data-name="Group 8" transform="translate(-573 2694.552)">
    <g id="Group_7" data-name="Group 7" transform="translate(685 3565)">
      <path id="Path_1" data-name="Path 1" d="M1579.236,217.91v-8.536h1.158l4.484,6.7v-6.7h1.082v8.536H1584.8l-4.483-6.708v6.708Z" transform="translate(-1561.508 -179.45)" fill="#1a1818" fill-rule="evenodd"/>
      <path id="Path_2" data-name="Path 2" d="M1596.794,236.306a3.406,3.406,0,0,0,.83,2.431,2.9,2.9,0,0,0,4.182-.007,3.631,3.631,0,0,0,.823-2.545,4.353,4.353,0,0,0-.353-1.82,2.688,2.688,0,0,0-1.032-1.205,2.767,2.767,0,0,0-1.523-.428,2.881,2.881,0,0,0-2.061.823A3.673,3.673,0,0,0,1596.794,236.306Zm-1.166-.016a4.637,4.637,0,0,1,1.143-3.329,3.878,3.878,0,0,1,2.947-1.2,4.1,4.1,0,0,1,2.13.565,3.691,3.691,0,0,1,1.447,1.575,5.1,5.1,0,0,1,.5,2.29,5.036,5.036,0,0,1-.523,2.326,3.594,3.594,0,0,1-1.487,1.552,4.251,4.251,0,0,1-2.071.526,4.039,4.039,0,0,1-2.156-.581,3.766,3.766,0,0,1-1.437-1.591A4.808,4.808,0,0,1,1595.628,236.29Z" transform="translate(-1524.35 -128.707)" fill="#1a1818" fill-rule="evenodd"/>
      <path id="Path_3" data-name="Path 3" d="M1586.016,233.194a3.409,3.409,0,0,0,.833,2.43,2.9,2.9,0,0,0,4.182-.007,3.628,3.628,0,0,0,.82-2.545,4.355,4.355,0,0,0-.35-1.82,2.686,2.686,0,0,0-1.032-1.205,2.774,2.774,0,0,0-1.522-.428,2.891,2.891,0,0,0-2.064.823A3.683,3.683,0,0,0,1586.016,233.194Zm-1.163-.016a4.656,4.656,0,0,1,1.14-3.329,3.886,3.886,0,0,1,2.947-1.2,4.1,4.1,0,0,1,2.133.565,3.707,3.707,0,0,1,1.447,1.575,5.14,5.14,0,0,1,.5,2.29,5.079,5.079,0,0,1-.523,2.326,3.594,3.594,0,0,1-1.487,1.552,4.254,4.254,0,0,1-2.074.526,4.035,4.035,0,0,1-2.153-.582,3.741,3.741,0,0,1-1.437-1.591A4.8,4.8,0,0,1,1584.854,233.178Zm-8.49,4.155V228.8h1.13v3.505h4.436V228.8h1.13v8.533h-1.13v-4.021h-4.436v4.021Z" transform="translate(-1568.019 -135.762)" fill="#1a1818" fill-rule="evenodd"/>
      <path id="Path_4" data-name="Path 4" d="M1649.673,221.226v-8.539h1.131v3.508h4.433v-3.508h1.131v8.539h-1.131V217.2H1650.8v4.025Zm-8.771-4.142a3.425,3.425,0,0,0,.836,2.431,2.888,2.888,0,0,0,4.174-.007,3.612,3.612,0,0,0,.824-2.545,4.212,4.212,0,0,0-.356-1.82,2.724,2.724,0,0,0-1.019-1.205,2.968,2.968,0,0,0-3.587.4A3.673,3.673,0,0,0,1640.9,217.083Zm-1.167-.016a4.637,4.637,0,0,1,1.144-3.329,3.886,3.886,0,0,1,2.946-1.2,4.127,4.127,0,0,1,2.136.565,3.69,3.69,0,0,1,1.438,1.575,5.106,5.106,0,0,1,.5,2.29,4.961,4.961,0,0,1-.526,2.326,3.52,3.52,0,0,1-1.486,1.552,4.237,4.237,0,0,1-2.064.526,4.061,4.061,0,0,1-2.163-.582,3.851,3.851,0,0,1-1.437-1.591A4.938,4.938,0,0,1,1639.735,217.067Z" transform="translate(-1424.367 -172.281)" fill="#1a1818" fill-rule="evenodd"/>
      <path id="Path_5" data-name="Path 5" d="M1635.386,207.521a3.424,3.424,0,0,0,.836,2.43,2.885,2.885,0,0,0,4.175-.01,3.586,3.586,0,0,0,.823-2.542,4.361,4.361,0,0,0-.343-1.82,2.731,2.731,0,0,0-2.555-1.633,2.9,2.9,0,0,0-2.064.823A3.684,3.684,0,0,0,1635.386,207.521Zm-1.166-.016a4.639,4.639,0,0,1,1.143-3.329,3.889,3.889,0,0,1,2.947-1.2,4.147,4.147,0,0,1,2.139.565,3.73,3.73,0,0,1,1.447,1.575,5.1,5.1,0,0,1,.493,2.293,4.952,4.952,0,0,1-.529,2.323,3.521,3.521,0,0,1-1.473,1.548,4.291,4.291,0,0,1-2.077.529,4.071,4.071,0,0,1-2.16-.581,3.806,3.806,0,0,1-1.437-1.591A4.906,4.906,0,0,1,1634.22,207.505Z" transform="translate(-1436.871 -193.956)" fill="#1a1818" fill-rule="evenodd"/>
      <line id="Line_26" data-name="Line 26" y1="10.85" x2="7.094" transform="translate(25.528 16.38)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_27" data-name="Line 27" x1="13.158" y1="16.38" transform="translate(19.464 0)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_28" data-name="Line 28" x1="19.464" y2="7.436" transform="translate(0 0)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_29" data-name="Line 29" x2="1.049" y2="20.849" transform="translate(0 7.436)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_30" data-name="Line 30" x2="13.262" y2="3.61" transform="translate(1.05 28.284)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_31" data-name="Line 31" x1="0.038" y2="20.825" transform="translate(39.292 44.214)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_32" data-name="Line 32" x1="0.029" y2="16.499" transform="translate(43.044 46.369)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_33" data-name="Line 33" x2="18.013" y2="10.319" transform="translate(39.292 65.039)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_34" data-name="Line 34" y1="10.201" x2="18.198" transform="translate(57.304 65.157)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_35" data-name="Line 35" y1="8.078" x2="14.414" transform="translate(57.324 62.963)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_36" data-name="Line 36" x1="0.092" y1="20.926" transform="translate(75.41 44.231)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_37" data-name="Line 37" x1="18.164" y1="10.466" transform="translate(57.247 33.765)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_38" data-name="Line 38" x1="14.389" y1="8.291" transform="translate(57.258 38.127)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_39" data-name="Line 39" x1="17.917" y2="10.449" transform="translate(39.33 33.765)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_40" data-name="Line 40" x1="11.108" y1="6.407" transform="translate(28.222 37.807)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_41" data-name="Line 41" x1="18.011" y2="10.557" transform="translate(21.281 65.039)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_42" data-name="Line 42" x1="17.99" y2="10.557" transform="translate(3.291 75.596)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_43" data-name="Line 43" x2="10.554" y2="17.938" transform="translate(21.281 75.596)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_44" data-name="Line 44" x1="10.588" y1="17.977" transform="translate(10.693 57.619)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_45" data-name="Line 45" x2="17.887" y2="10.406" transform="translate(75.503 65.157)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_46" data-name="Line 46" x1="0.037" y2="20.824" transform="translate(147.335 44.286)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_47" data-name="Line 47" x1="0.037" y2="16.475" transform="translate(151.081 46.449)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_48" data-name="Line 48" x2="18.277" y2="10.32" transform="translate(147.335 65.11)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_49" data-name="Line 49" y1="10.335" x2="17.933" transform="translate(165.612 65.096)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_50" data-name="Line 50" y1="8.194" x2="14.211" transform="translate(165.599 62.947)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_51" data-name="Line 51" x1="0.086" y1="20.927" transform="translate(183.458 44.168)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_52" data-name="Line 52" x1="18.031" y1="10.332" transform="translate(165.428 33.836)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_53" data-name="Line 53" x1="14.297" y1="8.19" transform="translate(165.428 38.152)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_54" data-name="Line 54" x1="18.056" y2="10.45" transform="translate(147.372 33.836)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_55" data-name="Line 55" x1="17.884" y2="10.423" transform="translate(129.452 65.11)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_56" data-name="Line 56" x1="17.931" y1="10.238" transform="translate(111.52 65.296)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_57" data-name="Line 57" x1="14.217" y1="8.118" transform="translate(111.513 69.571)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_58" data-name="Line 58" x1="18.13" y2="10.267" transform="translate(93.39 65.296)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_59" data-name="Line 59" x1="0.034" y2="20.91" transform="translate(93.355 75.563)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_60" data-name="Line 60" x1="0.028" y2="16.526" transform="translate(97.123 77.759)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_61" data-name="Line 61" x2="18.151" y2="10.321" transform="translate(93.355 96.473)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_62" data-name="Line 62" y1="10.343" x2="17.896" transform="translate(111.507 96.451)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_63" data-name="Line 63" y1="8.204" x2="14.201" transform="translate(111.492 94.3)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_64" data-name="Line 64" y1="20.917" x2="0.049" transform="translate(129.402 75.533)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_65" data-name="Line 65" x1="11.951" y2="7.085" transform="translate(81.404 96.473)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_66" data-name="Line 66" x1="12.176" y1="6.943" transform="translate(57.195 96.626)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_67" data-name="Line 67" x1="17.938" y2="10.442" transform="translate(39.257 96.626)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_68" data-name="Line 68" x1="11.791" y1="6.59" transform="translate(27.466 100.478)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_69" data-name="Line 69" y1="10.394" x2="18.08" transform="translate(183.458 33.775)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_70" data-name="Line 70" x2="11.951" y2="6.947" transform="translate(201.538 33.775)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_71" data-name="Line 71" y1="14.196" x2="0.025" transform="translate(199.672 20.653)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
      <line id="Line_72" data-name="Line 72" y1="14.2" x2="0.025" transform="translate(203.405 20.659)" fill="none" stroke="#1a1818" stroke-linecap="round" stroke-miterlimit="10" stroke-width="0.418"/>
    </g>
  </g>
  <text id="Erythema_Scaling_Dryness_" data-name="Erythema
Scaling
Dryness
" transform="translate(47 3865.477)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="16.527" y="12">Erythema</tspan><tspan x="21.291" y="37">Scaling</tspan><tspan x="19.821" y="62">Dryness</tspan></text>
  <text id="Stinging_Burning" data-name="Stinging/
Burning" transform="translate(47 3940.477)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="17.409" y="12">Stinging/</tspan><tspan x="20.109" y="24">Burning</tspan></text>
  <text id="Stinging_Burning-2" data-name="Stinging/
Burning" transform="translate(39 4079.477)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="25.909" y="12">Stinging/</tspan><tspan x="28.609" y="24">Burning</tspan></text>
  <text id="Face" transform="translate(46.775 3804)" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="26.702" y="12">Face</tspan></text>
  <text id="Trunk" transform="translate(56 3978)" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="15.915" y="12">Trunk</tspan></text>
  <text id="Erythema_Scaling_Dryness" data-name="Erythema
Scaling
Dryness" transform="translate(51 4005)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="13.098" y="12">Erythema</tspan><tspan x="17.862" y="37">Scaling</tspan><tspan x="16.392" y="62">Dryness</tspan></text>
  <path id="Path_6" data-name="Path 6" d="M0-30.049H337.176v322.17H0Z" transform="translate(47 3820.643)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <line id="Line_6" data-name="Line 6" x2="337.5" transform="translate(47 4075.466)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <line id="Line_7" data-name="Line 7" x2="337.5" transform="translate(47 4053.135)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <path id="Path_8" data-name="Path 8" d="M3.281,8.012H340.457" transform="translate(43.719 4019.395)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <line id="Line_9" data-name="Line 9" x2="337.5" transform="translate(47 4001.655)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <line id="Line_10" data-name="Line 10" x2="337.5" transform="translate(47 3887.916)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <path id="Path_10" data-name="Path 10" d="M0,0H337.5" transform="translate(47 3972.992)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <line id="Line_12" data-name="Line 12" x2="337.5" transform="translate(47 3936.253)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <line id="Line_13" data-name="Line 13" x2="337.5" transform="translate(47 3913.514)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <path id="Path_11" data-name="Path 11" d="M0,0H337.176" transform="translate(47 3861.735)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <path id="Path_7" data-name="Path 7" d="M2.816-17.01H339.527" transform="translate(44.184 3852.974)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <path id="Path_9" data-name="Path 9" d="M-17.208-38.222V72.886" transform="translate(307.286 4039.877)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <path id="Path_14" data-name="Path 14" d="M-17.208-38.222V72.623" transform="translate(358.286 4039.877)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <path id="Path_13" data-name="Path 13" d="M-17.208-38.222V72.623" transform="translate(269.708 4039.877)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <path id="Path_12" data-name="Path 12" d="M-17.208-38.222V72.623" transform="translate(227.286 4039.877)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <line id="Line_22" data-name="Line 22" y2="137.027" transform="translate(290.286 3835.965)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <line id="Line_94" data-name="Line 94" y2="137.027" transform="translate(341.286 3835.965)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <line id="Line_93" data-name="Line 93" y2="177.535" transform="translate(252.5 3835.965)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <line id="Line_92" data-name="Line 92" y2="137.027" transform="translate(208.286 3835.965)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <line id="Line_23" data-name="Line 23" y2="111" transform="translate(157.5 4001.5)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <line id="Line_24" data-name="Line 24" y2="137.027" transform="translate(157.857 3835.965)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <line id="Line_25" data-name="Line 25" y2="322" transform="translate(119.775 3790.5)" fill="none" stroke="#1a1818" stroke-width="0.5"/>
  <text id="N_1185" data-name="N=1185" transform="translate(263.675 3978)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="38.614" y="12">N=1185</tspan></text>
  <text id="_12.7_13.2_17.8_9.2_" data-name="12.7%
13.2%
17.8%
9.2%
" transform="translate(252.817 4007)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="6.343" y="12">12.7%</tspan><tspan x="6.217" y="36.5">13.2%</tspan><tspan x="6.499" y="61">17.8%</tspan><tspan x="7.753" y="85.5">9.2%</tspan></text>
  <text id="_4.4_2.6_3.9_2.2_" data-name="4.4%
2.6%
3.9%
2.2%
" transform="translate(301.45 4007)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="5.787" y="12">4.4%</tspan><tspan x="6.111" y="36.5">2.6%</tspan><tspan x="5.949" y="61">3.9%</tspan><tspan x="6.303" y="85.5">2.2%</tspan></text>
  <text id="Mild_21_23.7_29.9_15.9_" data-name="Mild 
21%
23.7%
29.9%
15.9%" transform="translate(252.817 3841)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan fill="#000"><tspan x="6.943" y="12">Mild </tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="9.589" y="36.5">21%</tspan><tspan x="5.569" y="61">23.7%</tspan><tspan x="5.131" y="85.5">29.9%</tspan><tspan x="5.725" y="110">15.9%</tspan></tspan></text>
  <text id="Moderate_6.8_5.9_6.8_3.8_" data-name="Moderate 
6.8%
5.9%
6.8%
3.8%
" transform="translate(291.45 3841)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan fill="#000"><tspan x="3.971" y="12">Moderate </tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="15.821" y="36.5">6.8%</tspan><tspan x="15.827" y="61">5.9%</tspan><tspan x="15.821" y="85.5">6.8%</tspan><tspan x="16.031" y="110">3.8%</tspan></tspan></text>
  <text id="AKLIEF_Cream_N_1214_Maximum_Severity_during_Treatment" data-name="AKLIEF Cream N=1214
Maximum Severity 
during Treatment" transform="translate(124.775 3791)" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="17.792" y="12">AKLIEF Cream N=1214</tspan><tspan x="24.134" y="24">Maximum Severity </tspan><tspan x="26.678" y="36">during Treatment</tspan></text>
  <text id="AKLIEF_Cream_N_1194_Maximum_Severity_during_Treatment" data-name="AKLIEF Cream N=1194
Maximum Severity 
during Treatment" transform="translate(256.775 3791)" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="17.6" y="12">AKLIEF Cream N=1194</tspan><tspan x="24.134" y="24">Maximum Severity </tspan><tspan x="26.678" y="36">during Treatment</tspan></text>
  <text id="N_1202" data-name="N=1202" transform="translate(128.775 3978)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="38.26" y="12">N=1202</tspan></text>
  <text id="_26.5_29.7_32.9_26.1_" data-name="26.5%
29.7%
32.9%
26.1%" transform="translate(120.231 4007)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="8.313" y="12">26.5%</tspan><tspan x="8.775" y="36.5">29.7%</tspan><tspan x="8.451" y="61">32.9%</tspan><tspan x="9.519" y="85.5">26.1%</tspan></text>
  <text id="_18.9_13.7_16.1_10.9_" data-name="18.9%
13.7%
16.1%
10.9%" transform="translate(162.408 4007)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="11.219" y="12">18.9%</tspan><tspan x="11.789" y="36.5">13.7%</tspan><tspan x="12.467" y="61">16.1%</tspan><tspan x="11.255" y="85.5">10.9%</tspan></text>
  <text id="_5.2_1.7_1.8_4.3_" data-name="5.2%
1.7%
1.8%
4.3%" transform="translate(214 4007)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="7.539" y="12">5.2%</tspan><tspan x="8.577" y="36.5">1.7%</tspan><tspan x="8.217" y="61">1.8%</tspan><tspan x="7.437" y="85.5">4.3%</tspan></text>
  <text id="Mild_30.6_37.5_39_35.6_" data-name="Mild
30.6%
37.5%
39%
35.6%" transform="translate(126.231 3841)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan fill="#000"><tspan x="4.715" y="12">Mild</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="2.825" y="36.5">30.6%</tspan><tspan x="3.569" y="61">37.5%</tspan><tspan x="6.251" y="85.5">39%</tspan><tspan x="2.795" y="110">35.6%</tspan></tspan></text>
  <text id="Moderate_28.4_27.1_29.7_20.6_" data-name="Moderate
28.4%
27.1%
29.7%
20.6%" transform="translate(161.408 3841)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan fill="#000"><tspan x="1.971" y="12">Moderate</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="11.553" y="36.5">28.4%</tspan><tspan x="13.527" y="61">27.1%</tspan><tspan x="12.003" y="85.5">29.7%</tspan><tspan x="11.643" y="110">20.6%</tspan></tspan></text>
  <text id="Severe_6.2_4.9_4.8_5.9_" data-name="Severe
6.2%
4.9%
4.8%
5.9%" transform="translate(213 3841)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan fill="#000"><tspan x="2.737" y="12">Severe</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="8.521" y="36.5">6.2%</tspan><tspan x="8.227" y="61">4.9%</tspan><tspan x="8.239" y="85.5">4.8%</tspan><tspan x="8.239" y="110">5.9%</tspan></tspan></text>
  <text id="_0.4_0.1_0.1_0.5_" data-name="0.4%
0.1%
0.1%
0.5%
" transform="translate(347.225 4007)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="7.899" y="12">0.4%</tspan><tspan x="9.117" y="36.5">0.1%</tspan><tspan x="9.117" y="61">0.1%</tspan><tspan x="7.911" y="85.5">0.5%</tspan></text>
  <text id="Severe_0.8_0.3_0.8_0.5_" data-name="Severe
0.8%
0.3%
0.8%
0.5%
" transform="translate(346.225 3841)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan fill="#000"><tspan x="3.325" y="12">Severe</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="8.869" y="36.5">0.8%</tspan><tspan x="9.067" y="61">0.3%</tspan><tspan x="8.869" y="85.5">0.8%</tspan><tspan x="8.911" y="110">0.5%</tspan><tspan x="17.887" y="134.5"></tspan></tspan></text>
  <g id="Group_39" data-name="Group 39" transform="translate(28 -119)">
    <text id="_Means_presented_in_table_are_Least_Square_LS_means" data-name="*Means presented in table are Least Square (LS) means" transform="translate(17 9601.996)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="12">*Means presented in table are Least Square (LS) means</tspan></text>
    <g id="Group_37" data-name="Group 37" transform="translate(0 24)">
      <g id="Group_9" data-name="Group 9" transform="translate(18.625 9250)">
        <rect id="Rectangle_3" data-name="Rectangle 3" width="338.375" height="319.233" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_73" data-name="Line 73" x2="338.375" transform="translate(0 236.353)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_74" data-name="Line 74" x2="338.375" transform="translate(0 152.473)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_75" data-name="Line 75" x2="338.375" transform="translate(0 73.635)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_76" data-name="Line 76" x2="247" transform="translate(90.875 27.151)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_77" data-name="Line 77" y2="292.523" transform="translate(276.813 26.977)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_78" data-name="Line 78" y2="319.5" transform="translate(213.5)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_79" data-name="Line 79" y2="292.523" transform="translate(154.188 26.977)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_80" data-name="Line 80" y2="319.5" transform="translate(90.875)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
      </g>
      <text id="IGA_Success_At_least_a_2-grade_improvement_and_Clear_0_or_Almost_Clear_1_" data-name="IGA Success
At least a 2-grade improvement 
and “Clear” (0) or “Almost Clear” (1)" transform="translate(22.625 9330.919)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan fill="#000"><tspan x="16.534" y="12">IGA Success</tspan></tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="5.47" y="24">At least a 2-grade </tspan><tspan x="14.842" y="36">improvement </tspan><tspan x="6.484" y="48">and “Clear” (0) or </tspan><tspan x="7.036" y="60">“Almost Clear” (1)</tspan></tspan></text>
      <text id="Inflammatory_Lesions_Mean_Absolute_Percent_Change_from_Baseline" data-name="Inflammatory Lesions
Mean* Absolute (Percent) 
Change from Baseline" transform="translate(30.625 9404.919)" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="5.252" y="12">Inflammatory </tspan><tspan x="18.47" y="24">Lesions</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="1.28" y="36">Mean* Absolute </tspan><tspan x="15.752" y="48">(Percent) </tspan><tspan x="7.166" y="60">Change from </tspan><tspan x="16.772" y="72">Baseline</tspan></tspan></text>
      <text id="Non-inflammatory_Lesions_Mean_Absolute_Percent_Change_from_Baseline" data-name="Non-inflammatory Lesions
Mean* Absolute (Percent) 
Change from Baseline" transform="translate(22.625 9488.919)" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="3.004" y="12">Non-inflammatory </tspan><tspan x="26.47" y="24">Lesions</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="9.28" y="36">Mean* Absolute </tspan><tspan x="23.752" y="48">(Percent) </tspan><tspan x="15.166" y="60">Change from </tspan><tspan x="24.772" y="72">Baseline</tspan></tspan></text>
      <text id="AKLIEF_Cream_N_612_" data-name="AKLIEF 
Cream 
(N= 612)" transform="translate(110 9279.47)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="16.82" y="12">AKLIEF </tspan><tspan x="16.388" y="24">Cream </tspan><tspan x="13.904" y="36">(N= 612)</tspan></text>
      <text id="_29.4_-19.0_-54.4_-25.0_-49.7_" data-name="29.4%




-19.0 
(-54.4%)




-25.0 
(-49.7%)" transform="translate(110 9358)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="19.16" y="12">29.4%</tspan><tspan x="30.374" y="26"></tspan><tspan x="30.374" y="40"></tspan><tspan x="30.374" y="54"></tspan><tspan x="30.374" y="68"></tspan><tspan x="20.996" y="82">-19.0 </tspan><tspan x="14" y="96">(-54.4%)</tspan><tspan x="30.374" y="110"></tspan><tspan x="30.374" y="124"></tspan><tspan x="30.374" y="138"></tspan><tspan x="30.374" y="152"></tspan><tspan x="20.126" y="166">-25.0 </tspan><tspan x="14.492" y="180">(-49.7%)</tspan></text>
      <text id="Study_1" data-name="Study 1" transform="translate(186.326 9267.337)" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="-15.15" y="0">Study 1</tspan></text>
      <text id="Vehicle_Cream_N_596_" data-name="Vehicle 
Cream
(N= 596)" transform="translate(173.252 9279.47)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="14.854" y="12">Vehicle </tspan><tspan x="15.388" y="24">Cream</tspan><tspan x="11.722" y="36">(N= 596)</tspan></text>
      <text id="_19.5_-15.4_-44.8_-17.9_-35.7_" data-name="19.5%




-15.4 
(-44.8%)




-17.9 
(-35.7%)" transform="translate(173.252 9358)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="18.892" y="12">19.5%</tspan><tspan x="29.374" y="26"></tspan><tspan x="29.374" y="40"></tspan><tspan x="29.374" y="54"></tspan><tspan x="29.374" y="68"></tspan><tspan x="19.828" y="82">-15.4 </tspan><tspan x="12.958" y="96">(-44.8%)</tspan><tspan x="29.374" y="110"></tspan><tspan x="29.374" y="124"></tspan><tspan x="29.374" y="138"></tspan><tspan x="29.374" y="152"></tspan><tspan x="20.548" y="166">-17.9 </tspan><tspan x="13.498" y="180">(-35.7%)</tspan></text>
      <text id="Study_2" data-name="Study 2" transform="translate(298.577 9267.337)" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="-15.744" y="0">Study 2</tspan></text>
      <text id="AKLIEF_Cream_N_602_" data-name="AKLIEF 
Cream 
(N= 602)
" transform="translate(232.245 9279.47)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="17.82" y="12">AKLIEF </tspan><tspan x="17.388" y="24">Cream </tspan><tspan x="13.878" y="36">(N= 602)</tspan><tspan x="31.374" y="48"></tspan></text>
      <text id="_42.3_-24.2_-66.2_-30.1_-57.7_" data-name=" 42.3%




-24.2 
(-66.2%)




-30.1 
(-57.7%)" transform="translate(232.245 9358)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="19.17" y="12" xml:space="preserve"> 42.3%</tspan><tspan x="31.374" y="26"></tspan><tspan x="31.374" y="40"></tspan><tspan x="31.374" y="54"></tspan><tspan x="31.374" y="68"></tspan><tspan x="21.414" y="82">-24.2 </tspan><tspan x="15.192" y="96">(-66.2%)</tspan><tspan x="31.374" y="110"></tspan><tspan x="31.374" y="124"></tspan><tspan x="31.374" y="138"></tspan><tspan x="31.374" y="152"></tspan><tspan x="22.056" y="166">-30.1 </tspan><tspan x="16.164" y="180">(-57.7%)</tspan></text>
      <text id="Vehicle_Cream_N_610_" data-name="Vehicle 
Cream
(N=610)
" transform="translate(295 9279.47)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="16.354" y="12">Vehicle </tspan><tspan x="16.888" y="24">Cream</tspan><tspan x="15.298" y="36">(N=610)</tspan></text>
      <text id="_25.7_-18.7_-51.2_-21.6_-43.9_" data-name=" 25.7%




-18.7 
(-51.2%)




-21.6 
(-43.9%)" transform="translate(295 9358)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="18.754" y="12" xml:space="preserve"> 25.7%</tspan><tspan x="30.874" y="26"></tspan><tspan x="30.874" y="40"></tspan><tspan x="30.874" y="54"></tspan><tspan x="30.874" y="68"></tspan><tspan x="21.652" y="82">-18.7 </tspan><tspan x="15.826" y="96">(-51.2%)</tspan><tspan x="30.874" y="110"></tspan><tspan x="30.874" y="124"></tspan><tspan x="30.874" y="138"></tspan><tspan x="30.874" y="152"></tspan><tspan x="21.616" y="166">-21.6 </tspan><tspan x="14.65" y="180">(-43.9%)</tspan></text>
    </g>
  </g>
  <g id="Group_40" data-name="Group 40" transform="translate(28 -132)">
    <text id="_Means_presented_in_table_are_Least_Square_LS_means-2" data-name="*Means presented in table are Least Square (LS) means" transform="translate(17 10025.996)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="0" y="12">*Means presented in table are Least Square (LS) means</tspan></text>
    <g id="Group_38" data-name="Group 38" transform="translate(0 447)">
      <g id="Group_9-2" data-name="Group 9" transform="translate(18.625 9250)">
        <rect id="Rectangle_3-2" data-name="Rectangle 3" width="338.375" height="319.233" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_73-2" data-name="Line 73" x2="338.375" transform="translate(0 236.353)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_74-2" data-name="Line 74" x2="338.375" transform="translate(0 152.473)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_75-2" data-name="Line 75" x2="338.375" transform="translate(0 73.635)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_76-2" data-name="Line 76" x2="247" transform="translate(90.875 27.151)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_77-2" data-name="Line 77" y2="292.523" transform="translate(276.813 26.977)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_78-2" data-name="Line 78" y2="319.5" transform="translate(213.5)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_79-2" data-name="Line 79" y2="292.523" transform="translate(154.188 26.977)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
        <line id="Line_80-2" data-name="Line 80" y2="319.5" transform="translate(90.875)" fill="none" stroke="#1a1818" stroke-miterlimit="10" stroke-width="0.5"/>
      </g>
      <text id="PGA_Success_At_least_a_2-grade_improvement_and_Clear_0_or_Almost_Clear_1_" data-name="PGA Success
At least a 2-grade improvement and “Clear” (0) or “Almost Clear” (1)" transform="translate(22.625 9330.919)" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="15.196" y="12">PGA Success</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="5.47" y="24">At least a 2-grade </tspan><tspan x="5.566" y="36">improvement and </tspan><tspan x="15.802" y="48">“Clear” (0) or </tspan><tspan x="7.036" y="60">“Almost Clear” (1)</tspan></tspan></text>
      <text id="Inflammatory_Lesions_Mean_Absolute_Percent_Change_from_Baseline-2" data-name="Inflammatory Lesions
Mean* Absolute (Percent) 
Change from Baseline" transform="translate(30.625 9404.919)" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="5.252" y="12">Inflammatory </tspan><tspan x="18.47" y="24">Lesions</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="1.28" y="36">Mean* Absolute </tspan><tspan x="15.752" y="48">(Percent) </tspan><tspan x="7.166" y="60">Change from </tspan><tspan x="16.772" y="72">Baseline</tspan></tspan></text>
      <text id="Non-inflammatory_Lesions_Mean_Absolute_Percent_Change_from_Baseline-2" data-name="Non-inflammatory Lesions
Mean* Absolute (Percent) 
Change from Baseline" transform="translate(22.625 9488.919)" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="3.004" y="12">Non-inflammatory </tspan><tspan x="26.47" y="24">Lesions</tspan><tspan font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="9.28" y="36">Mean* Absolute </tspan><tspan x="23.752" y="48">(Percent) </tspan><tspan x="15.166" y="60">Change from </tspan><tspan x="24.772" y="72">Baseline</tspan></tspan></text>
      <text id="AKLIEF_Cream_N_600_" data-name="AKLIEF 
Cream 
(N= 600)" transform="translate(110 9279.47)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="16.82" y="12">AKLIEF </tspan><tspan x="16.388" y="24">Cream </tspan><tspan x="12.614" y="36">(N= 600)</tspan></text>
      <text id="_35.7_-21.4_-57.4_-21.9_-49.1_" data-name="35.7%




-21.4 
(-57.4%)




-21.9 
(-49.1%)" transform="translate(110 9358)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="19.274" y="12">35.7%</tspan><tspan x="30.374" y="26"></tspan><tspan x="30.374" y="40"></tspan><tspan x="30.374" y="54"></tspan><tspan x="30.374" y="68"></tspan><tspan x="21.05" y="82">-21.4 </tspan><tspan x="14.834" y="96">(-57.4%)</tspan><tspan x="30.374" y="110"></tspan><tspan x="30.374" y="124"></tspan><tspan x="30.374" y="138"></tspan><tspan x="30.374" y="152"></tspan><tspan x="21.008" y="166">-21.9 </tspan><tspan x="15.38" y="180">(-49.1%)</tspan></text>
      <text id="Study_1-2" data-name="Study 1" transform="translate(186.326 9267.337)" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="-15.15" y="0">Study 1</tspan></text>
      <text id="Vehicle_Cream_N_585" data-name="Vehicle 
Cream
(N= 585" transform="translate(173.252 9279.47)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="14.854" y="12">Vehicle </tspan><tspan x="15.388" y="24">Cream</tspan><tspan x="13.174" y="36">(N= 585</tspan></text>
      <text id="_25.0_-18.8_-50.0_-17.8_-40.3_" data-name="25.0%




-18.8 
(-50.0%)




-17.8 
(-40.3%)" transform="translate(173.252 9358)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="18.076" y="12">25.0%</tspan><tspan x="29.374" y="26"></tspan><tspan x="29.374" y="40"></tspan><tspan x="29.374" y="54"></tspan><tspan x="29.374" y="68"></tspan><tspan x="19.792" y="82">-18.8 </tspan><tspan x="13.084" y="96">(-50.0%)</tspan><tspan x="29.374" y="110"></tspan><tspan x="29.374" y="124"></tspan><tspan x="29.374" y="138"></tspan><tspan x="29.374" y="152"></tspan><tspan x="20.56" y="166">-17.8 </tspan><tspan x="13.198" y="180">(-40.3%)</tspan></text>
      <text id="Study_2-2" data-name="Study 2" transform="translate(298.577 9267.337)" font-size="12" font-family="SofiaProCondensed-Bold, Sofia Pro Condensed" font-weight="700"><tspan x="-15.744" y="0">Study 2</tspan></text>
      <text id="AKLIEF_Cream_N_598_" data-name="AKLIEF 
Cream 
(N= 598)
" transform="translate(232.245 9279.47)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="17.82" y="12">AKLIEF </tspan><tspan x="17.388" y="24">Cream </tspan><tspan x="13.746" y="36">(N= 598)</tspan><tspan x="31.374" y="48"></tspan></text>
      <text id="_42.6_-25.5_-65.4_-25.9_-55.2_" data-name="42.6%




-25.5 
(-65.4%)




-25.9 
(-55.2%)" transform="translate(232.245 9358)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="20.178" y="12">42.6%</tspan><tspan x="31.374" y="26"></tspan><tspan x="31.374" y="40"></tspan><tspan x="31.374" y="54"></tspan><tspan x="31.374" y="68"></tspan><tspan x="21.096" y="82">-25.5 </tspan><tspan x="14.952" y="96">(-65.4%)</tspan><tspan x="31.374" y="110"></tspan><tspan x="31.374" y="124"></tspan><tspan x="31.374" y="138"></tspan><tspan x="31.374" y="152"></tspan><tspan x="21.042" y="166">-25.9 </tspan><tspan x="15.27" y="180">(-55.2%)</tspan></text>
      <text id="Vehicle_Cream_N_609_" data-name="Vehicle 
Cream
(N=609)
" transform="translate(295 9279.47)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="16.354" y="12">Vehicle </tspan><tspan x="16.888" y="24">Cream</tspan><tspan x="14.272" y="36">(N=609)</tspan></text>
      <text id="_29.9_-19.8_-51.1_-20.8_-45.1_" data-name="29.9%




-19.8 
(-51.1%)




-20.8 
(-45.1%)" transform="translate(295 9358)" fill="#1a1818" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300"><tspan x="19.618" y="12">29.9%</tspan><tspan x="30.874" y="26"></tspan><tspan x="30.874" y="40"></tspan><tspan x="30.874" y="54"></tspan><tspan x="30.874" y="68"></tspan><tspan x="21.424" y="82">-19.8 </tspan><tspan x="16.786" y="96">(-51.1%)</tspan><tspan x="30.874" y="110"></tspan><tspan x="30.874" y="124"></tspan><tspan x="30.874" y="138"></tspan><tspan x="30.874" y="152"></tspan><tspan x="20.584" y="166">-20.8 </tspan><tspan x="15.718" y="180">(-45.1%)</tspan></text>
    </g>
  </g>
</svg>


<!-- end of testing something here -->








<svg class="desktop" xmlns="http://www.w3.org/2000/svg" width="768" height="180" viewBox="0 0 768 180">
    <text id="Marketed_by:_GALDERMA_LABORATORIES_L.P._Fort_Worth_Texas_76177_USA_All_trademarks_are_the_property_of_their_respective_owners._Made_in_Canada_This_Patient_Information_has_been_approved_by_the_U.S._Food_and_Drug_Administration._Issued:_10_2019_P54485-" data-name="Marketed by: GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA All trademarks are the property of their respective owners. Made in Canada This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 10/2019P54485-" font-size="16" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="12">Marketed by:</tspan>
        <tspan x="0" y="31">GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA</tspan>
        <tspan x="0" y="50">All trademarks are the property of their respective owners.</tspan>
        <tspan x="0" y="69">Made in Canada</tspan>
        <tspan x="0" y="88"></tspan>
        <tspan x="0" y="107">This Patient Information has been approved by the U.S. Food and Drug Administration. </tspan>
        <tspan x="0" y="126">Issued: 10/2019</tspan>
        <tspan x="0" y="145"></tspan>
        <tspan x="0" y="164">P54485-1</tspan>
    </text>
</svg>
<svg class="mobile" xmlns="http://www.w3.org/2000/svg" width="768" height="180" viewBox="0 0 768 180">
    <text id="Marketed_by:_GALDERMA_LABORATORIES_L.P._Fort_Worth_Texas_76177_USA_All_trademarks_are_the_property_of_their_respective_owners._Made_in_Canada_This_Patient_Information_has_been_approved_by_the_U.S._Food_and_Drug_Administration._Issued:_10_2019_P54485-" data-name="Marketed by: GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA All trademarks are the property of their respective owners. Made in Canada This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 10/2019P54485-" font-size="12" font-family="SofiaProCondensed-Light, Sofia Pro Condensed" font-weight="300">
        <tspan x="0" y="12">Marketed by:</tspan>
        <tspan x="0" y="31">GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA</tspan>
        <tspan x="0" y="50">All trademarks are the property of their respective owners.</tspan>
        <tspan x="0" y="69">Made in Canada</tspan>
        <tspan x="0" y="88"></tspan>
        <tspan x="0" y="107">This Patient Information has been approved by the U.S. Food</tspan>
        <tspan x="0" y="126">and Drug Administration.  Issued: 10/2019</tspan>
        <tspan x="0" y="145"></tspan>
        <tspan x="0" y="164">P54485-1</tspan>
    </text>
</svg>
</div>
</div>














